General Information of This Antigen
Antigen ID
TAR0FPXYP
Antigen Name
Undisclosed
Gene Name
Undisclosed
Each Antibody-drug Conjuate AND It's Component Related to This Antigen
Full List of The ADC Related to This Antigen
ADC Info ADC Name Payload Target Linker Ref
wO2024131835A1 ADC-04
Undisclosed
Undisclosed
Undisclosed
[1]
ADC Info ADC Name Payload Target Linker Ref
wO2024131835A1 ADC-05
Undisclosed
Undisclosed
Undisclosed
[1]
wO2024131835A1 ADC-14
Undisclosed
Undisclosed
Undisclosed
[1]
ADC Info ADC Name Payload Target Linker Ref
wO2024131835A1 ADC-06
Undisclosed
Undisclosed
Undisclosed
[1]
ADC Info ADC Name Payload Target Linker Ref
jP2024501894A5-8
Undisclosed
Undisclosed
Undisclosed
[2]
jP2024501894A5-16
Undisclosed
Undisclosed
Undisclosed
[2]
jP2024501894A5-18
Undisclosed
Undisclosed
Undisclosed
[2]
jP2024501894A5-19
Undisclosed
Undisclosed
Undisclosed
[2]
23C2 Her2-2
ADC Info ADC Name Payload Target Linker Ref
eP4183421A1 23C2 Her2-2-DXD
Exatecan
Undisclosed
EP4183421A1+Trastuzumab-DXD+Linker
[3]
eP4183421A1 23C2 Her2-2-DDDXD
Exatecan
Undisclosed
EP4183421A1+Trastuzumab-DDDXD+Linker
[3]
cN114569739A 23C2 Her2-2-DXD
Undisclosed
Undisclosed
Undisclosed
[4]
cN114569739A ADC-1 (23C2 Her2-2)
Undisclosed
Undisclosed
Undisclosed
[4]
cN114569739A ADC-2 (23C2 Her2-2)
Undisclosed
Undisclosed
Undisclosed
[4]
cN114569739A ADC-3 (23C2 Her2-2)
Undisclosed
Undisclosed
Undisclosed
[4]
cN114569739A ADC-4 (23C2 Her2-2)
Undisclosed
Undisclosed
Undisclosed
[4]
cN114569739A ADC-5 (23C2 Her2-2)
Undisclosed
Undisclosed
Undisclosed
[4]
cN114569739A ADC-6 (23C2 Her2-2)
Undisclosed
Undisclosed
Undisclosed
[4]
cN114569739A ADC-7 (23C2 Her2-2)
Undisclosed
Undisclosed
Undisclosed
[4]
cN114569739A ADC-8 (23C2 Her2-2)
Undisclosed
Undisclosed
Undisclosed
[4]
345A12-14AAS
ADC Info ADC Name Payload Target Linker Ref
cN119630431A ADC-9
CN119630431A-ADC-1-PAYLOAD
Undisclosed
Undisclosed
[5]
cN119630431A ADC-10
CN119630431A-ADC-1-PAYLOAD
Undisclosed
CN119630431A-ADC-3-LINKER
[5]
cN119630431A ADC-11
CN119630431A-ADC-1-PAYLOAD
Undisclosed
CN119630431A-ADC-5-LINKER
[5]
ADC Info ADC Name Payload Target Linker Ref
Monoclonal antibody 45-2D9-haematoporphyrin conjugate
Hematoporphyrin
Undisclosed
Undisclosed
[6]
ADC Info ADC Name Payload Target Linker Ref
wO2024131835A1 ADC-01
Undisclosed
Undisclosed
Undisclosed
[1]
ADC Info ADC Name Payload Target Linker Ref
wO2024131835A1 ADC-02
Undisclosed
Undisclosed
Undisclosed
[1]
wO2024131835A1 ADC-12
Undisclosed
Undisclosed
Undisclosed
[1]
7D12-fGly
ADC Info ADC Name Payload Target Linker Ref
39138197 7D12-fGly MNB-Pyra
MNB-Pyra
Undisclosed
Undisclosed
[7]
ADC Info ADC Name Payload Target Linker Ref
wO2024131835A1 ADC-03
Undisclosed
Undisclosed
Undisclosed
[1]
wO2024131835A1 ADC-13
Undisclosed
Undisclosed
Undisclosed
[1]
wO2024131835A1 ADC-20
Undisclosed
Undisclosed
Undisclosed
[1]
wO2024131835A1 ADC-22
Undisclosed
Undisclosed
Undisclosed
[1]
wO2024131835A1 ADC-24
Undisclosed
Undisclosed
Undisclosed
[1]
a therapeutic human IgG4 mAb
ADC Info ADC Name Payload Target Linker Ref
40037092 ADC-1
Undisclosed
Undisclosed
Undisclosed
[8]
40037092 ADC-2
Undisclosed
Undisclosed
Undisclosed
[8]
ADC Info ADC Name Payload Target Linker Ref
39757732 ADC1
Monomethyl auristatin E
Undisclosed
D1 Linker
[9]
39757732 ADC2
PBD dimer
Undisclosed
D2 Linker
[9]
39757732 ADC3
Monomethyl auristatin E
Undisclosed
D3 Linker
[9]
39757732 ADC4
DX-8951 derivative (DXd)
DNA topoisomerase 1 (TOP1)
D4 Linker
[9]
ADC Info ADC Name Payload Target Linker Ref
wO2024131835A1 ADC-10
Undisclosed
Undisclosed
Undisclosed
[1]
WO2024131835A1 ADC-18 (ABBV-399 analogue)
Undisclosed
Undisclosed
Undisclosed
[1]
ADC Info ADC Name Payload Target Linker Ref
AHK-PABC-Exa
Exatecan
Undisclosed
Mc-Val-Cit-PABC
[10]
Anti-B-cell mAb SN7
ADC Info ADC Name Payload Target Linker Ref
Monoclonal antibody SN7-ricin chain A conjugate
Deglycosylated ricin A-chain (dgA)
Undisclosed
Undisclosed
[11]
Anti-mAb303
ADC Info ADC Name Payload Target Linker Ref
TW202444426A ADC-301
Undisclosed
Undisclosed
Undisclosed
[12]
TW202444426A ADC-043-A
Undisclosed
Undisclosed
Undisclosed
[12]
TW202444426A ADC-043-B
Undisclosed
Undisclosed
Undisclosed
[12]
TW202444426A ADC-302
Undisclosed
Undisclosed
Undisclosed
[12]
TW202444426A ADC-045-A
Undisclosed
Undisclosed
Undisclosed
[12]
TW202444426A ADC-046-B
Undisclosed
Undisclosed
Undisclosed
[12]
TW202444426A ADC-303
Undisclosed
Undisclosed
Undisclosed
[12]
Anti-mAb304
ADC Info ADC Name Payload Target Linker Ref
TW202444426A ADC-031
Undisclosed
Undisclosed
Undisclosed
[12]
TW202444426A ADC-310-A
Undisclosed
Undisclosed
Undisclosed
[12]
TW202444426A ADC-311-B
Undisclosed
Undisclosed
Undisclosed
[12]
TW202444426A ADC-032
Undisclosed
Undisclosed
Undisclosed
[12]
TW202444426A ADC-312-A
Undisclosed
Undisclosed
Undisclosed
[12]
TW202444426A ADC-313-B
Undisclosed
Undisclosed
Undisclosed
[12]
TW202444426A ADC-033
Undisclosed
Undisclosed
Undisclosed
[12]
TW202444426A ADC-034
Undisclosed
Undisclosed
Undisclosed
[12]
Anti-mAb305
ADC Info ADC Name Payload Target Linker Ref
TW202444426A ADC-027
Undisclosed
Undisclosed
Undisclosed
[12]
TW202444426A ADC-028
Undisclosed
Undisclosed
Undisclosed
[12]
TW202444426A ADC-304
Undisclosed
Undisclosed
Undisclosed
[12]
TW202444426A ADC-305-A
Undisclosed
Undisclosed
Undisclosed
[12]
TW202444426A ADC-306-B
Undisclosed
Undisclosed
Undisclosed
[12]
TW202444426A ADC-307
Undisclosed
Undisclosed
Undisclosed
[12]
TW202444426A ADC-308-A
Undisclosed
Undisclosed
Undisclosed
[12]
TW202444426A ADC-309-B
Undisclosed
Undisclosed
Undisclosed
[12]
anti-mPD-L1
ADC Info ADC Name Payload Target Linker Ref
AU2020291014A1 IC-46
AU2020291014A1-Payload-35
Undisclosed
Undisclosed
[13]
Anti-TPP-5442
ADC Info ADC Name Payload Target Linker Ref
US12144865B2 31t-4
Undisclosed
Undisclosed
Undisclosed
[14]
US12144865B2 34t-4
Undisclosed
Undisclosed
Undisclosed
[14]
Anti-TPP-7511
ADC Info ADC Name Payload Target Linker Ref
US12144865B2 34te-4
Undisclosed
Undisclosed
Undisclosed
[14]
ADC Info ADC Name Payload Target Linker Ref
ARKRA-PABC-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[10]
Azido Modified XMT-1604
ADC Info ADC Name Payload Target Linker Ref
jP2024501894A5-1
Undisclosed
Undisclosed
Undisclosed
[2]
ADC Info ADC Name Payload Target Linker Ref
wO2024131835A1 ADC-11
Undisclosed
Undisclosed
Undisclosed
[1]
wO2024131835A1 ADC-19
Undisclosed
Undisclosed
Undisclosed
[1]
uS20230285580A1 B12-B1
B4 Payload
Deoxyribonucleic acid (DNA)
US20230285580A1 B12-B2 linker
[15]
uS20230285580A1 B12-B2
US20230285580A1 B12-B3 payload
Undisclosed
US20230285580A1 B12-B2 linker
[15]
uS20230285580A1 B12-B3
US20230285580A1 B12-B3 payload
Undisclosed
US20230285580A1 B12-B6 linker
[15]
uS20230285580A1 B12-B4
US20230285580A1 B12-B4 payload
Undisclosed
US20230285580A1 B12-B6 linker
[15]
uS20230285580A1 B12-B6
B4 Payload
Deoxyribonucleic acid (DNA)
US20230285580A1 B12-B6 linker
[15]
ADC Info ADC Name Payload Target Linker Ref
CA1-vedotin
Monomethyl auristatin E
Undisclosed
Mc-Val-Cit-PABC
[16]
ADC Info ADC Name Payload Target Linker Ref
cANO01-MC-MMAF
Monomethyl auristatin F
Microtubule (MT)
Maleimidocaproyl (me) linker
[17]
CEA.5GlfhL2
ADC Info ADC Name Payload Target Linker Ref
AU2020291014A1 IC-51
AU2020291014A1-Payload-49
Undisclosed
Undisclosed
[13]
AU2020291014A1 IC-57
AU2020291014A1-Payload-35
Undisclosed
Undisclosed
[13]
CEA.9-G1fhL2
ADC Info ADC Name Payload Target Linker Ref
AU2020291014A1 IC-81
AU2020291014A1-Payload-77
Undisclosed
Undisclosed
[13]
AU2020291014A1 IC-82
AU2020291014A1-Payload-72
Undisclosed
Aminobenzazepine-linker Formula II-72
[13]
AU2020291014A1 IC-83
AU2020291014A1-Payload-74
Undisclosed
Undisclosed
[13]
AU2020291014A1 IC-84
AU2020291014A1-Payload-80
Undisclosed
Aminobenzazepine-linker Formula II-80
[13]
CEA.9-GlfhL2
ADC Info ADC Name Payload Target Linker Ref
AU2020291014A1 IC-67
AU2020291014A1-Payload-41
Undisclosed
Undisclosed
[13]
AU2020291014A1 IC-68
AU2020291014A1-Payload-35
Undisclosed
Undisclosed
[13]
AU2020291014A1 IC-69
AU2020291014A1-Payload-69
Undisclosed
Aminobenzazepine-linker Formula II-69
[13]
control mouse IgG
ADC Info ADC Name Payload Target Linker Ref
Nonbinding control-ADC
Monomethyl auristatin E
Undisclosed
Mc-Val-Cit-PABC
[18]
Control mouse IgG
ADC Info ADC Name Payload Target Linker Ref
Non-binding IgG -ADC
Monomethyl auristatin E
Undisclosed
Mc-Val-Cit-PABC
[19]
Goat anti-mouse IgG
ADC Info ADC Name Payload Target Linker Ref
IgG-p (HEMA-co-MPS)
p (HEMA-co-MPS)
Undisclosed
HEMA linker
[20]
H1H21234N
ADC Info ADC Name Payload Target Linker Ref
H1H21234N-compound 25
Undisclosed
Undisclosed
Undisclosed
[21]
H1H6958N2
ADC Info ADC Name Payload Target Linker Ref
h1H6958N2-N297Q-Ex23 4
Undisclosed
Undisclosed
Undisclosed
[22]
h1H6958N2-N297Q-Ex22 4
Undisclosed
Undisclosed
Undisclosed
[22]
h1H6958N2-N297Q-Ex19
Undisclosed
Undisclosed
Undisclosed
[22]
h1H6958N2-N297Q-Ex20
Undisclosed
Undisclosed
Undisclosed
[22]
h1H6958N2-N297Q-Ex23 3.9
Undisclosed
Undisclosed
Undisclosed
[22]
h1H6958N2-N297Q-Ex22 3.9
Undisclosed
Undisclosed
Undisclosed
[22]
h1H6958N2-N297Q-Ex24
Undisclosed
Undisclosed
Undisclosed
[22]
ADC Info ADC Name Payload Target Linker Ref
hIgG1-MMAE (gylcan conjugation)
Monomethyl auristatin E
Undisclosed
Undisclosed
[23]
hIgG1-MMAE (Lysine conjugation)
Monomethyl auristatin E
Undisclosed
Undisclosed
[23]
CN116916962A-ADC-B14
Compound I-5c
Undisclosed
CN116916962A-C-18-linker
[24]
CN116916962A-ADC-B15
Compound I-5c
Undisclosed
CN116916962A-C-30-linker
[24]
CN116916962A-ADC-B16
Compound I-5c
Undisclosed
CN116916962A-C-41-linker
[24]
CN116916962A-ADC-B17
Compound No.14
Undisclosed
CN116916962A-C-38-linker
[24]
CN116916962A-ADC-B18
Compound I-5c
Undisclosed
CN116916962A-C-18-linker
[24]
CN116916962A-ADC-B19
Compound I-5c
Undisclosed
CN116916962A-C-39-linker
[24]
CN116916962A-ADC-B20
Compound No.14
Undisclosed
CN116916962A-C-38-linker
[24]
ADC Info ADC Name Payload Target Linker Ref
HK-PABC-Exa
Exatecan
Undisclosed
Mc-Val-Cit-PABC
[10]
ADC Info ADC Name Payload Target Linker Ref
HKA-PABC-Exa
Exatecan
Undisclosed
Mc-Val-Cit-PABC
[10]
ADC Info ADC Name Payload Target Linker Ref
wO2024140449A1 ADC1
WO2024140449A1+ADC1+payload
Undisclosed
Mc-Val-Cit
[25]
wO2024140449A1 ADC3
WO2024140449A1+ADC1+payload
Undisclosed
WO2024140449A1+ADC3+Linker
[25]
wO2024140449A1 ADC5
WO2024140449A1+ADC5+payload
DNA topoisomerase I (TOP1)
WO2024140449A1+ADC5+Linker
[25]
wO2024140449A1 ADC7
WO2024140449A1+ADC5+payload
DNA topoisomerase I (TOP1)
WO2024140449A1+ADC7+Linker
[25]
wO2024140449A1 ADC9
WO2024140449A1+ADC5+payload
DNA topoisomerase I (TOP1)
WO2024140449A1+ADC9+Linker
[25]
wO2024140449A1 ADC11
WO2024140449A1+ADC5+payload
DNA topoisomerase I (TOP1)
WO2024140449A1+ADC9+Linker
[25]
wO2024140449A1 ADC13
WO2024140449A1+ADC13+payload
Undisclosed
WO2024140449A1+ADC13+Linker
[25]
wO2024140449A1 ADC15
WO2024140449A1+ADC13+payload
Undisclosed
WO2024140449A1+ADC13+Linker
[25]
wO2024140449A1 ADC17
WO2024140449A1+ADC17+payload
Undisclosed
WO2024140449A1+ADC17+Linker
[25]
wO2024140449A1 ADC19
WO2024140449A1+ADC19+payload
Undisclosed
WO2024140449A1+ADC19+Linker
[25]
wO2024140449A1 ADC21
WO2024140449A1+ADC5+payload
DNA topoisomerase I (TOP1)
WO2024140449A1+ADC5+Linker
[25]
cN117159739A ADC3
undisclosed
Undisclosed
Undisclosed
[26]
cN117159739A ADC4
undisclosed
Undisclosed
Undisclosed
[26]
cN117159739A ADC6
undisclosed
Undisclosed
Undisclosed
[26]
ADC Info ADC Name Payload Target Linker Ref
hu1084-MMAE-DAR3
Monomethyl auristatin E
Undisclosed
Mc-Val-Cit-PABC
[27]
hu1084-MMAE-DAR8
Monomethyl auristatin E
Undisclosed
Mc-Val-Cit-PABC
[27]
hu1084-DXd-DAR3
DX-8951 derivative (DXd)
DNA topoisomerase 1 (TOP1)
Mc-Gly-Gly-Phe-Gly
[27]
hu1084-DXd-DAR8
DX-8951 derivative (DXd)
DNA topoisomerase 1 (TOP1)
Mc-Gly-Gly-Phe-Gly
[27]
hu2H11_R35-74
ADC Info ADC Name Payload Target Linker Ref
uS11998611B2 ADC1
Undisclosed
Undisclosed
Undisclosed
[28]
uS11998611B2 ADC3
Undisclosed
Undisclosed
Undisclosed
[28]
uS11998611B2 Ex.3
Undisclosed
Undisclosed
Undisclosed
[28]
uS11998611B2 Ex.6
Undisclosed
Undisclosed
Undisclosed
[28]
uS11998611B2 Ex.16
Undisclosed
Undisclosed
Undisclosed
[28]
uS11998611B2 Ex.19
Undisclosed
Undisclosed
Undisclosed
[28]
uS11998611B2 Ex.23
Undisclosed
Undisclosed
Undisclosed
[28]
uS11998611B2 Ex.26
Undisclosed
Undisclosed
Undisclosed
[28]
uS11998611B2 Ex.29
Undisclosed
Undisclosed
Undisclosed
[28]
uS11998611B2 Ex.32
Undisclosed
Undisclosed
Undisclosed
[28]
hu2H11_R35-75
ADC Info ADC Name Payload Target Linker Ref
uS11998611B2 ADC2
Undisclosed
Undisclosed
Undisclosed
[28]
ADC Info ADC Name Payload Target Linker Ref
hu5B1-TCO
Undisclosed
Undisclosed
Undisclosed
huCDCP1 (F30-T667 Q525)-8xHis_T3
ADC Info ADC Name Payload Target Linker Ref
aU2023308528A1 ADC4
Exatecan
Undisclosed
Mal-amido-PEG8-acid
[29]
aU2023308528A1 mAb-vcMMAE (DAR of 4)
Undisclosed
Undisclosed
Undisclosed
[29]
aU2023308528A1 ADC3 (DAR of 8)
Exatecan
Undisclosed
Mal-amido-PEG8-acid
[29]
ADC Info ADC Name Payload Target Linker Ref
eP4161582A4 Compound 3
EP4161582A4+Compound 3+payload
Undisclosed
EP4161582A4+Compound 3+Linker
[30]
dBCO-vc-MMAE
Monomethyl auristatin E
Microtubule (MT)
EP4161582A4+DBCO-vc-MMAE+Linker
[30]
dBCO-S-DM1
Mertansine DM1
Undisclosed
DBCO-PEG3-amine
[30]
dBCO-vc-seco DUBA
seco-DUBA
Undisclosed
EP4161582A4+DBCO-vc-seco DUBA+Linker
[30]
dBCO-DTPA
seco-DUBA
Undisclosed
EP4161582A4+DBCO-DTPA+Linker
[30]
dBCO-PEG3-vc-Exatecan
Exatecan
Undisclosed
DBCO-PEG3 linker
[30]
dBCO-PEG3-GGFG-Exatecan
Exatecan
Undisclosed
EP4161582A4+DBCO-PEG3-GGFG-Exatecan+Linker
[30]
dBCO-PEG12-GGFG-Exatecan
Exatecan
Undisclosed
EP4161582A4+DBCO-PEG12-GGFG-Exatecan+Linker
[30]
dBCO-PEG3-GGFG-DXd2
EP4161582A4+DBCO-PEG3-GGFG-DXd2+payload
Undisclosed
DBCO-PEG3 linker
[30]
dBCO-PEG12-GGFG-DXd2
EP4161582A4+DBCO-PEG12-GGFG-DXd2+payload
Undisclosed
EP4161582A4+DBCO-PEG12-GGFG-DXd2+Linker
[30]
bCN-PEG3-VC-PAB-MMAE
Monomethyl auristatin E
Microtubule (MT)
EP4161582A4+BCN-PEG3-VC-PAB-MMAE+Linker
[30]
bCN-PEG12-GGFG-Exatecan
Exatecan
Undisclosed
EP4161582A4+BCN-PEG12-GGFG-Exatecan +Linker
[30]
bCN-PEG12-GGFG-DXd2
EP4161582A4+BCN-PEG12-GGFG-DXd2 +Linker
Undisclosed
EP4161582A4+BCN-PEG12-GGFG-DXd2 +Linker
[30]
dBCO-PEG3-2 (PEG3-VC-PAB-MMAE)
Monomethyl auristatin E
Microtubule (MT)
EP4161582A4+DBCO-PEG3-2 (PEG3-VC-PAB-MMAE)+Linker
[30]
dCBPR2002-4 (DBCO-vc-MMAE)
Undisclosed
Undisclosed
Undisclosed
dCBPR2002-4 (DBCO-S-DM1)
Undisclosed
Undisclosed
Undisclosed
dCBPR2002-4 (DBCO-vc-seco DUBA)
Undisclosed
Undisclosed
Undisclosed
dCBPR2002-4 (DBCO-PEG4-vc-PAB-MMAF)
Undisclosed
Undisclosed
Undisclosed
dCBPR2002-4 (DBCO-DTPA)
Undisclosed
Undisclosed
Undisclosed
dCBPR2002-4 (DBCO-PEG3-vc-Exatecan )
Undisclosed
Undisclosed
Undisclosed
dCBPR2002-4 (DBCO-PEG3-GGFG-Exatecan)
Undisclosed
Undisclosed
Undisclosed
dCBPR2002-4 (DBCO-PEG12-GGFG-Exatecan)
Undisclosed
Undisclosed
Undisclosed
dCBPR2002-4 (DBCO-PEG3-GGFG-DXd2)
Undisclosed
Undisclosed
Undisclosed
dCBPR2002-4 (DBCO-PEG12-GGFG-DXd2)
Undisclosed
Undisclosed
Undisclosed
dCBPR2002-4 (BCN-PEG3-VC-PAB-MMAE)
Undisclosed
Undisclosed
Undisclosed
dCBPR2002-4 (BCN-PEG12-GGFG-Exatecan)
Undisclosed
Undisclosed
Undisclosed
dCBPR2002-4 (BCN-PEG3-GGFG-Exatecan)
Undisclosed
Undisclosed
Undisclosed
dCBPR2002-4 (BCN-PEG12-GGFG-DXd2)
Undisclosed
Undisclosed
Undisclosed
dCBPR2002-4 (DBCO-PEG3-2 (PEG3-VC-PAB-MMAE))
Undisclosed
Undisclosed
Undisclosed
dCBPR2002-2 (DBCO-vc-MMAE)-2 (DBCO-vc-seco DUBA)
Undisclosed
Undisclosed
Undisclosed
dCBPR2002-2 (DBCO-vc-MMAE)-2 (DBCO-S-DM1)
Undisclosed
Undisclosed
Undisclosed
dCBPR2002-2 (DBCO-vc-seco DUBA)-2 (DBCO-S-DM1)
Undisclosed
Undisclosed
Undisclosed
ADC Info ADC Name Payload Target Linker Ref
uS11661457B2 Ab-E-11
US11661457B2+Ab-E-11+payload
Undisclosed
Mc-Val-Cit-PABC
[31]
uS11661457B2 Ab-E-12
US11661457B2+Ab-E-12+payload
Microtubule (MT)
Mc-Val-Cit-PABC
[31]
uS11661457B2 Ab-G-12
US11661457B2+Ab-E-12+payload
Microtubule (MT)
6-Maleimidocaproic acid
[31]
uS11661457B2 Ab-E-13
US11661457B2+Ab-E-13+payload
Undisclosed
US11661457B2+Ab-E-13+Linker
[31]
uS11661457B2 Ab-F-13
US11661457B2+Ab-F-13+payload
Undisclosed
US11661457B2+Ab-F-13+Linker
[31]
uS11661457B2 Ab-G-13
US11661457B2+Ab-G-13+payload
Undisclosed
6-Maleimidocaproic acid
[31]
uS11661457B2 Ab-E-15
US11661457B2+Ab-E-15+payload
Undisclosed
Mc-Val-Cit-PABC
[31]
uS11661457B2 Ab-G-15
US11661457B2+Ab-G-15+payload
Undisclosed
6-Maleimidocaproic acid
[31]
uS11661457B2 Ab-F-61
US11661457B2+Ab-F-61+payload
Undisclosed
US11661457B2+Ab-F-13+Linker
[31]
uS11661457B2 Ab-F-62
US11661457B2+Ab-F-62+payload
Undisclosed
US11661457B2+Ab-F-13+Linker
[31]
uS11661457B2 Ab-F-63
US11661457B2+Ab-F-63+payload
Undisclosed
US11661457B2+Ab-F-13+Linker
[31]
IL13Ra2-AB08-v1.0
ADC Info ADC Name Payload Target Linker Ref
uS11365263B2 ADC#1
US11365263B2 ADC#6 payload
Undisclosed
US11365263B2 ADC#6 linker
[32]
IN202417078684A+Ab1
ADC Info ADC Name Payload Target Linker Ref
IN202417078684A+ADC1
Mertansine DM1
Undisclosed
Succinimidyl-4- (N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
[33]
IN202417078684A+Ab2
ADC Info ADC Name Payload Target Linker Ref
IN202417078684A+ADC2
Mertansine DM1
Undisclosed
Succinimidyl-4- (N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
[33]
IN202417078684A+Ab3
ADC Info ADC Name Payload Target Linker Ref
IN202417078684A+ADC3
Mertansine DM1
Undisclosed
Succinimidyl-4- (N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
[33]
IN202417078684A+Ab4
ADC Info ADC Name Payload Target Linker Ref
IN202417078684A+ADC4
Mertansine DM1
Undisclosed
Succinimidyl-4- (N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
[33]
IN202417078684A+ADC5
Mertansine DM4
Undisclosed
SPDB
[33]
IN202417078684A+ADC6
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[33]
IN202417078684A+ADC7
DX-8951 derivative (DXd)
DNA topoisomerase 1 (TOP1)
Mc-Gly-Gly-Phe-Gly
[33]
IN202417078684A+ADC8
DX-8951 derivative (DXd)
DNA topoisomerase 1 (TOP1)
Mc-Gly-Gly-Phe-Gly
[33]
IN202417078684A+ADC9
Monomethyl auristatin F
Microtubule (MT)
Mc-Val-Cit-PABC
[33]
IN202417078684A+ADC10
Active metabolite of irinotecan SN38
Undisclosed
Undisclosed
[33]
ADC Info ADC Name Payload Target Linker Ref
mC-VC-PAB-MMAE
Undisclosed
Undisclosed
CN116196428A+MC-VC-PAB-MMAE+Linker
[34]
ADC Info ADC Name Payload Target Linker Ref
KAR-PABC-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[10]
ADC Info ADC Name Payload Target Linker Ref
KM8047-SG3249
SG3199
Undisclosed
Undisclosed
[35]
ADC Info ADC Name Payload Target Linker Ref
lY203725
4-desacetylvinblastine (DAVLB)
Microtubule (MT)
A cleavable linker
lY256787
4-desacetylvinblastine (DAVLB)
Microtubule (MT)
A cleavable linker
ADC Info ADC Name Payload Target Linker Ref
lR004-VC-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[36]
lsotype control mAb3
ADC Info ADC Name Payload Target Linker Ref
wO2023173132A1 ADC-2
P9
Undisclosed
IBAC-suC-PEG4
[37]
wO2023173132A1 ADC-4
P9
Undisclosed
DIBAC-suC-PEG8
[37]
wO2023173132A1 ADC-6
P9
Undisclosed
DIBAC-suC-PEG12
[37]
wO2023173132A1 ADC-15
P9
Undisclosed
Undisclosed
[37]
wO2023173132A1 ADC-29
P8 Payload
Undisclosed
NH2-PEG8-triazole
[37]
M30-H1-L-4P
ADC Info ADC Name Payload Target Linker Ref
uS12186310B2-1
Undisclosed
Undisclosed
Mc-Gly-Gly-Phe-Gly
[38]
uS12186310B2-2
Undisclosed
Undisclosed
Undisclosed
[38]
uS12186310B2-3
Undisclosed
Undisclosed
Undisclosed
[38]
uS12186310B2-4
Undisclosed
Undisclosed
Undisclosed
[38]
uS12186310B2-5
Undisclosed
Undisclosed
Undisclosed
[38]
uS12186310B2-12
Undisclosed
Undisclosed
Undisclosed
[38]
uS12186310B2-13
Undisclosed
Undisclosed
Undisclosed
[38]
uS12186310B2-14
Undisclosed
Undisclosed
Undisclosed
[38]
uS12186310B2-15
Undisclosed
Undisclosed
Undisclosed
[38]
uS12186310B2-16
Undisclosed
Undisclosed
Undisclosed
[38]
uS12186310B2-17
Undisclosed
Undisclosed
Undisclosed
[38]
uS12186310B2-18
Undisclosed
Undisclosed
Undisclosed
[38]
uS12186310B2-19
Undisclosed
Undisclosed
Undisclosed
[38]
uS12186310B2-20
Undisclosed
Undisclosed
Undisclosed
[38]
uS12186310B2-21
Undisclosed
Undisclosed
Undisclosed
[38]
uS12186310B2-23
Undisclosed
Undisclosed
Undisclosed
[38]
uS12186310B2-24
Undisclosed
Undisclosed
Undisclosed
[38]
uS12186310B2-25
Undisclosed
Undisclosed
Undisclosed
[38]
uS12186310B2-26
Undisclosed
Undisclosed
Undisclosed
[38]
uS12186310B2-27
Undisclosed
Undisclosed
Undisclosed
[38]
uS12186310B2-28
Undisclosed
Undisclosed
Undisclosed
[38]
uS12186310B2-29
Undisclosed
Undisclosed
Undisclosed
[38]
uS12186310B2-30
Undisclosed
Undisclosed
Undisclosed
[38]
uS12186310B2-38
Undisclosed
Undisclosed
Undisclosed
[38]
uS12186310B2-39
Undisclosed
Undisclosed
Undisclosed
[38]
uS12186310B2-40
Undisclosed
Undisclosed
Undisclosed
[38]
uS12186310B2-41
Undisclosed
Undisclosed
Undisclosed
[38]
uS12186310B2-42
Undisclosed
Undisclosed
Undisclosed
[38]
uS12186310B2-43
Undisclosed
Undisclosed
Undisclosed
[38]
uS12186310B2-44
Undisclosed
Undisclosed
Undisclosed
[38]
uS12186310B2-45
Undisclosed
Undisclosed
Undisclosed
[38]
uS12186310B2-46
Undisclosed
Undisclosed
Undisclosed
[38]
uS12186310B2-50
Undisclosed
Undisclosed
Undisclosed
[38]
uS12186310B2-51
Undisclosed
Undisclosed
Undisclosed
[38]
uS12186310B2-52
Undisclosed
Undisclosed
Undisclosed
[38]
uS12186310B2-53
Undisclosed
Undisclosed
Undisclosed
[38]
uS12186310B2-54
Undisclosed
Undisclosed
Undisclosed
[38]
uS12186310B2-55
Undisclosed
Undisclosed
Undisclosed
[38]
uS12186310B2-56
Undisclosed
Undisclosed
Undisclosed
[38]
ADC Info ADC Name Payload Target Linker Ref
WO2024140927A1-ADC-B (DAR4)
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[39]
mAb1DesignA
ADC Info ADC Name Payload Target Linker Ref
mAb1DesignA-SLAE
SLAuristatin E derivate
Undisclosed
DBCO-C4-PEG3-VC-PABC
[40]
mAb1DesignA-LLAE
LLAuristatin E derivate
Undisclosed
DBCO-C6-PEG8-VC-PABC-AE
[40]
mAb1DesignB
ADC Info ADC Name Payload Target Linker Ref
mAb1DesignB-SLAE
SLAuristatin E derivate
Undisclosed
DBCO-C4-PEG3-VC-PABC
[40]
mAb1DesignB-LLAE
LLAuristatin E derivate
Undisclosed
DBCO-C6-PEG8-VC-PABC-AE
[40]
mAb1DesignC
ADC Info ADC Name Payload Target Linker Ref
mAb1DesignC-SLAE
SLAuristatin E derivate
Undisclosed
DBCO-C4-PEG3-VC-PABC
[40]
mAb1DesignC-LLAE
LLAuristatin E derivate
Undisclosed
DBCO-C6-PEG8-VC-PABC-AE
[40]
mAb2DesignA
ADC Info ADC Name Payload Target Linker Ref
mAb2DesignA-SLAE
SLAuristatin E derivate
Undisclosed
DBCO-C4-PEG3-VC-PABC
[40]
mAb2DesignA-LLAE
LLAuristatin E derivate
Undisclosed
DBCO-C6-PEG8-VC-PABC-AE
[40]
mAb2DesignB
ADC Info ADC Name Payload Target Linker Ref
mAb2DesignB-SLAE
SLAuristatin E derivate
Undisclosed
DBCO-C4-PEG3-VC-PABC
[40]
mAb2DesignB-LLAE
LLAuristatin E derivate
Undisclosed
DBCO-C6-PEG8-VC-PABC-AE
[40]
mAb2DesignC
ADC Info ADC Name Payload Target Linker Ref
mAb2DesignC-SLAE
SLAuristatin E derivate
Undisclosed
DBCO-C4-PEG3-VC-PABC
[40]
mAb2DesignC-LLAE
LLAuristatin E derivate
Undisclosed
DBCO-C6-PEG8-VC-PABC-AE
[40]
Masked chicken-derived anti-IgM (aIgM) antibody
ADC Info ADC Name Payload Target Linker Ref
algM ADC
Monomethyl auristatin E
Undisclosed
DBCO-PEG4-Val-Cit-PABC
[41]
ADC Info ADC Name Payload Target Linker Ref
cN112638426B ADC1
Tubulin inhibitor B
Microtubule (MT)
CN112638426B +ADC1+Linker
[42]
cN112638426B ADC2
Tubulin inhibitor B
Microtubule (MT)
CN112638426B +ADC2+Linker
[42]
ADC Info ADC Name Payload Target Linker Ref
control surrogate and mouse SG
Active metabolite of irinotecan SN38
Undisclosed
CL2A
[43]
Mouse IgG2a
ADC Info ADC Name Payload Target Linker Ref
Mouse IgG2a-Val-Cit-Pab-MMAE
Monomethyl auristatin E
Undisclosed
Undisclosed
[23]
Mouse IgG2a-PEG8-MMAE
Monomethyl auristatin E
Undisclosed
Undisclosed
[23]
ADC Info ADC Name Payload Target Linker Ref
murinized SG
Active metabolite of irinotecan SN38
Undisclosed
CL2A
[43]
Neg-8-8-H16-K222R- hGl
ADC Info ADC Name Payload Target Linker Ref
Neg-8-8-H16-K222R- hGl-LP19
Undisclosed
Undisclosed
Undisclosed
[44]
Neg-8-8-H16-K222R-hG1
ADC Info ADC Name Payload Target Linker Ref
Neg-8-8-H16-K222R- hG1 -LP1
Undisclosed
Undisclosed
Undisclosed
[44]
Neg-8-8-H16-K222R-hGl
ADC Info ADC Name Payload Target Linker Ref
Neg-8-8-H16-K222R- hGl -LP13
Undisclosed
Undisclosed
Undisclosed
[44]
ADC Info ADC Name Payload Target Linker Ref
wO2024131835A1 ADC-09
Undisclosed
Undisclosed
Undisclosed
[1]
wO2024131835A1 ADC-17
Undisclosed
Undisclosed
Undisclosed
[1]
ADC Info ADC Name Payload Target Linker Ref
wO2024131835A1 ADC-07
Undisclosed
Undisclosed
Undisclosed
[1]
wO2024131835A1 ADC-15
Undisclosed
Undisclosed
Undisclosed
[1]
wO2024131835A1 ADC-21
Undisclosed
Undisclosed
Undisclosed
[1]
wO2024131835A1 ADC-23
Undisclosed
Undisclosed
Undisclosed
[1]
wO2024131835A1 ADC-25
Undisclosed
Undisclosed
Undisclosed
[1]
ADC Info ADC Name Payload Target Linker Ref
wO2024131835A1 ADC-08
Undisclosed
Undisclosed
Undisclosed
[1]
wO2024131835A1 ADC-16
Undisclosed
Undisclosed
Undisclosed
[1]
Nontargeting antibody control 1- 25
ADC Info ADC Name Payload Target Linker Ref
Nontargeting antibody control 1- 25
Undisclosed
Undisclosed
Undisclosed
[21]
Nontargeting antibody control 1- 36
ADC Info ADC Name Payload Target Linker Ref
Nontargeting antibody control 1- 36
Undisclosed
Undisclosed
Undisclosed
[21]
Nontargeting antibody control 1- rifalog
ADC Info ADC Name Payload Target Linker Ref
Nontargeting antibody control 1- rifalog
Undisclosed
Undisclosed
Undisclosed
[21]
Nontargeting antibody control 1- rifampicin N
ADC Info ADC Name Payload Target Linker Ref
Nontargeting antibody control 1- rifampicin N
Undisclosed
Undisclosed
Undisclosed
[21]
PDL1.24-G1f
ADC Info ADC Name Payload Target Linker Ref
AU2020291014A1 IC-36
AU2020291014A1-Payload-40
Undisclosed
Undisclosed
[13]
AU2020291014A1 IC-37
AU2020291014A1-Payload-39
Undisclosed
Undisclosed
[13]
AU2020291014A1 IC-72
AU2020291014A1-Payload-35
Undisclosed
Undisclosed
[13]
PDL1.85-G1f
ADC Info ADC Name Payload Target Linker Ref
AU2020291014A1 IC-48
AU2020291014A1-Payload-49
Undisclosed
Undisclosed
[13]
AU2020291014A1 IC-49
AU2020291014A1-Payload-49
Undisclosed
Undisclosed
[13]
AU2020291014A1 IC-73
AU2020291014A1-Payload-35
Undisclosed
Undisclosed
[13]
AU2020291014A1 IC-85
AU2020291014A1-Payload-69
Undisclosed
Aminobenzazepine-linker Formula II-69
[13]
AU2020291014A1 IC-88
AU2020291014A1-Payload-77
Undisclosed
Undisclosed
[13]
AU2020291014A1 IC-89
AU2020291014A1-Payload-74
Undisclosed
Undisclosed
[13]
ADC Info ADC Name Payload Target Linker Ref
pR300159-B81
NZ818359A+PR300159-B81+payload
Undisclosed
NZ818359A+PR300159-B81+Linker
[45]
pR300159-B71
NZ818359A+PR300159-B81+payload
Undisclosed
NZ818359A+PR300159-B71+Linker
[45]
PR300159-8
ADC Info ADC Name Payload Target Linker Ref
pR300159-8-B81
NZ818359A+PR300159-B81+payload
Undisclosed
NZ818359A+PR300159-B81+Linker
[45]
ADC Info ADC Name Payload Target Linker Ref
pR300186-B81
NZ818359A+PR300159-B81+payload
Undisclosed
NZ818359A+PR300159-B81+Linker
[45]
pR300186-B71
NZ818359A+PR300159-B81+payload
Undisclosed
NZ818359A+PR300159-B71+Linker
[45]
PR300186-10
ADC Info ADC Name Payload Target Linker Ref
pR300186-10-B81
NZ818359A+PR300159-B81+payload
Undisclosed
NZ818359A+PR300159-B81+Linker
[45]
Protease-activated chicken-derived anti-IgM (aIgM) antibody
ADC Info ADC Name Payload Target Linker Ref
Masked Protease-activated CH2-aIgM ADC
Monomethyl auristatin E
Undisclosed
DBCO-PEG4-Val-Cit-PABC
[41]
ADC Info ADC Name Payload Target Linker Ref
surrogate SG
Active metabolite of irinotecan SN38
Undisclosed
CL2A
[43]
Rabbit derived VL single-domain Anti-ody
ADC Info ADC Name Payload Target Linker Ref
VL-DAB31-SN38
Active metabolite of irinotecan SN38
DNA topoisomerase 1 (TOP1)
Mal-Cyc-PEG3-DAB
[46]
ROS-responsive SN38 ADC
Active metabolite of irinotecan SN38
DNA topoisomerase 1 (TOP1)
Mal-Cyc-PEG3-DAB
[46]
rat IgG2b
ADC Info ADC Name Payload Target Linker Ref
AU2020291014A1 IC-47
AU2020291014A1-Payload-35
Undisclosed
Undisclosed
[13]
ADC Info ADC Name Payload Target Linker Ref
RKAA-PABC-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[10]
ADC Info ADC Name Payload Target Linker Ref
RKAAR-PABC-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[10]
RKAAR-PABC-Exa
Exatecan
Undisclosed
Mc-Val-Cit-PABC
[10]
RKAAR-EDA-CS
cortisol
Undisclosed
Undisclosed
[10]
ROSPATAMAB
ADC Info ADC Name Payload Target Linker Ref
iGAC-92
IG-L-18 Payload
Undisclosed
IG-L-25 linker
[47]
ADC Info ADC Name Payload Target Linker Ref
RRK-PABC-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[10]
RRK-PABC-Exa
Exatecan
Undisclosed
Mc-Val-Cit-PABC
[10]
ADC Info ADC Name Payload Target Linker Ref
RRKAY-PABC-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[10]
ADC Info ADC Name Payload Target Linker Ref
CN119019562A ADC1 S-49-8
Monomethyl auristatin E
Undisclosed
Mc-Val-Cit-PABC
[48]
CN119019562A ADC2 S-49-8
Monomethyl auristatin E
Undisclosed
Mc-Val-Cit-PABC
[48]
CN119019562A ADC3 S-49-8
Monomethyl auristatin E
Undisclosed
Mc-Val-Cit-PABC
[48]
CN119019562A ADC4 S-49-8
Monomethyl auristatin E
Undisclosed
Mc-Val-Cit-PABC
[48]
ADC Info ADC Name Payload Target Linker Ref
CN119019562A ADC1 S-60-6
Monomethyl auristatin E
Undisclosed
Mc-Val-Cit-PABC
[48]
CN119019562A ADC2 S-60-6
Monomethyl auristatin E
Undisclosed
Mc-Val-Cit-PABC
[48]
CN119019562A ADC3 S-60-6
Monomethyl auristatin E
Undisclosed
Mc-Val-Cit-PABC
[48]
CN119019562A ADC4 S-60-6
Monomethyl auristatin E
Undisclosed
Mc-Val-Cit-PABC
[48]
ADC Info ADC Name Payload Target Linker Ref
KR1020250011922A ADC-S423
Undisclosed
Undisclosed
Undisclosed
[49]
ADC Info ADC Name Payload Target Linker Ref
KR1020250011922A ADC-S426
Undisclosed
Undisclosed
Undisclosed
[49]
ADC Info ADC Name Payload Target Linker Ref
WO2024105206A1 16i-5657 1
Undisclosed
Undisclosed
Undisclosed
[50]
WO2024105206A1 17i-5657 1
Undisclosed
Undisclosed
Undisclosed
[50]
WO2024105206A1 18i-5657 1
Undisclosed
Undisclosed
Undisclosed
[50]
WO2024105206A1 19i-5657 1
Undisclosed
Undisclosed
Undisclosed
[50]
WO2024105206A1 20i-5657 1
Undisclosed
Undisclosed
Undisclosed
[50]
WO2024105206A1 21i-5657 1
Undisclosed
Undisclosed
Undisclosed
[50]
WO2024105206A1 22i-5657 1
Undisclosed
Undisclosed
Undisclosed
[50]
WO2024105206A1 23i-5657 1
Undisclosed
Undisclosed
Undisclosed
[50]
WO2024105206A1 24i-5657 1
Undisclosed
Undisclosed
Undisclosed
[50]
WO2024105206A1 25i-5657 1
Undisclosed
Undisclosed
Undisclosed
[50]
WO2024105206A1 26i-5657 1
Undisclosed
Undisclosed
Undisclosed
[50]
WO2024105206A1 27i-5657 1
Undisclosed
Undisclosed
Undisclosed
[50]
WO2024105206A1 28i-5657 1
Undisclosed
Undisclosed
Undisclosed
[50]
WO2024105206A1 33i-5657 1
Undisclosed
Undisclosed
Undisclosed
[50]
WO2024105206A1 35i-5657 1
Undisclosed
Undisclosed
Undisclosed
[50]
WO2024105206A1 41i-5657 1
Undisclosed
Undisclosed
Undisclosed
[50]
WO2024105206A1 16i-5657 2
Mdo-cpt
DNA topoisomerase I (TOP1)
16i-5657 Linker
[50]
WO2024105206A1 17i-5657 2
41i-5657 Payload
Undisclosed
17i-5657 Linker
[50]
WO2024105206A1 18i-5657 2
41i-5657 Payload
Undisclosed
18i-5657 Linker
[50]
WO2024105206A1 19i-5657 2
Mdo-cpt
DNA topoisomerase I (TOP1)
6i-5657 Linker
[50]
WO2024105206A1 20i-5657 2
41i-5657 Payload
Undisclosed
17i-5657 Linker
[50]
WO2024105206A1 21i-5657 2
41i-5657 Payload
Undisclosed
21i-5657 Linker
[50]
WO2024105206A1 22i-5657 2
22i-5657 Payload
Undisclosed
22i-5657 Linker
[50]
WO2024105206A1 23i-5657 2
Mdo-cpt
DNA topoisomerase I (TOP1)
23i-5657 Linker
[50]
WO2024105206A1 24i-5657 2
41i-5657 Payload
Undisclosed
24i-5657 Linker
[50]
WO2024105206A1 25i-5657 2
Undisclosed
Undisclosed
Undisclosed
[50]
WO2024105206A1 26i-5657 2
Undisclosed
Undisclosed
Undisclosed
[50]
WO2024105206A1 27i-5657 2
Mdo-cpt
DNA topoisomerase I (TOP1)
22i-5657 Linker
[50]
WO2024105206A1 28i-5657 2
Mdo-cpt
DNA topoisomerase I (TOP1)
6i-5657 Linker
[50]
WO2024105206A1 33i-5657 2
Monomethyl auristatin E
Microtubule (MT)
22i-5657 Linker
[50]
WO2024105206A1 35i-5657 2
41i-5657 Payload
Undisclosed
22i-5657 Linker
[50]
WO2024105206A1 41i-5657 2
41i-5657 Payload
Undisclosed
41i-5657 Linker
[50]
wO2024105206A1 1i-5657
CHH0170, 1i-5657, Payload
Undisclosed
32p-Avelu Linker
[50]
wO2024105206A1 2i-5657
Camptothecin
Undisclosed
2i-5657 Linker
[50]
wO2024105206A1 3i-5657
Ac-Exatecan
DNA topoisomerase I (TOP1)
32p-Avelu Linker
[50]
wO2024105206A1 4i-5657
CHH0177, 4i-5657, Payload
Undisclosed
CHH0177, 4i-5657, Linker
[50]
wO2024105206A1 5i-5657
CHH0177, 4i-5657, Payload
Undisclosed
3i-5657 Linker
[50]
wO2024105206A1 6i-5657
6i-5657 Payload
DNA topoisomerase I (TOP1)
3i-5657 Linker
[50]
wO2024105206A1 7i-5657
CHH0183, 7i-5657, Payload
Undisclosed
Undisclosed
[50]
wO2024105206A1 8i-5657
Mdo-cpt
DNA topoisomerase I (TOP1)
Undisclosed
[50]
wO2024105206A1 9i-5657
Undisclosed
Undisclosed
Undisclosed
[50]
wO2024105206A1 10i-5657
Ac-Exatecan
DNA topoisomerase I (TOP1)
CHH0187, 10i-5657, Linker
[50]
wO2024105206A1 11i-5657
Undisclosed
Undisclosed
Undisclosed
[50]
wO2024105206A1 12i-5657
CHH0189, 12i-5657, Payload
Undisclosed
CHH0189, 12i-5657, Linker
[50]
wO2024105206A1 13i-5657
CHH0191, 13i-5657, Payload
Undisclosed
CHH0191, 13i-5657, Linker
[50]
wO2024105206A1 14i-5657
CHH0192, 14i-5657, Payload 1; CHH0192, 14i-5657, Payload 2
Undisclosed
CHH0192, 14i-5657, Linker1; CHH0192, 14i-5657, Linker2
[50]
wO2024105206A1 15i-5657
CHH0193, 15i-5657, Payload 1; CHH0193, 15i-5657, Payload 2
Undisclosed
Undisclosed
[50]
Tras-Glf-N297A
ADC Info ADC Name Payload Target Linker Ref
AU2020291014A1 IC-58
AU2020291014A1-Payload-35
Undisclosed
Undisclosed
[13]
AU2020291014A1 IC-64
AU2020291014A1-Payload-69
Undisclosed
Aminobenzazepine-linker Formula II-69
[13]
ADC Info ADC Name Payload Target Linker Ref
Tz-IR700
IRDye 700DX
Undisclosed
NHS ester linker
[51]
ADC Info ADC Name Payload Target Linker Ref
YTH24.5-SG3249
Undisclosed
Undisclosed
Undisclosed
[52]
YTH24.5-SG3376
Undisclosed
Undisclosed
Undisclosed
[52]
undisclosed
ADC Info ADC Name Payload Target Linker Ref
dS3610
Undisclosed
Stimulator of interferon genes protein (STING1)
Undisclosed
DB-1202
Undisclosed
Undisclosed
Undisclosed
PHN-010
TOP1 inhibitor
DNA topoisomerase 1 (TOP1)
Undisclosed
SC-007
PBD dimer
Human deoxyribonucleic acid (hDNA)
Undisclosed
SC-005
PBD dimer
Human deoxyribonucleic acid (hDNA)
Undisclosed
[53]
IgG2-ADC
Undisclosed
Undisclosed
Undisclosed
[272]
Anti-0079b_AsnAsnPABC_MMAE
Monomethyl auristatin E
Undisclosed
AsnAsnPABC
[273]
FG-ADC (DAR 4)
Mertansine DM1
Undisclosed
MA-FG-P12
[274]
FG-ADC (DAR 8)
Mertansine DM1
Undisclosed
MA-FG-P12
[274]
VAG-ADC (DAR 4)
Mertansine DM1
Undisclosed
MA-VAG-P12
[274]
VAG-ADC (DAR 8)
Mertansine DM1
Undisclosed
MA-VAG-P12
[274]
Control to 8D302-MMAE
Monomethyl auristatin E
Undisclosed
Mc-Val-Cit-PABC
[275]
Control to 8D302-DXd
DX-8951 derivative (DXd)
DNA topoisomerase 1 (TOP1)
Mc-Gly-Gly-Phe-Gly
[275]
Isotype-SG3249
SG3199
Undisclosed
Undisclosed
[52]
Isotype-SG3376
SG3199
Undisclosed
Undisclosed
[52]
IgG-MMAE 8
Monomethyl auristatin E
Undisclosed
Mc-Val-Cit-PABC
[276]
Control-MMAE-DAR3
Monomethyl auristatin E
Undisclosed
Mc-Val-Cit-PABC
[27]
Control-DXd-DAR8
DX-8951 derivative (DXd)
DNA topoisomerase 1 (TOP1)
Mc-Gly-Gly-Phe-Gly
[27]
39298786 ADC2 (DAR8)
AZ14170132
Undisclosed
Val-Ala-PEG8
[277]
39298786 ADC2 (DAR4)
AZ14170132
Undisclosed
Val-Ala-PEG8
[277]
38770747 ADC 1 (DAR 2)
Undisclosed
Undisclosed
Undisclosed
[278]
38770747 ADC 2 (DAR 2)
Undisclosed
Undisclosed
Undisclosed
[278]
38770747 ADC 3 (DAR 2)
Undisclosed
Undisclosed
Undisclosed
[278]
38770747 ADC 4 (DAR 2)
Undisclosed
Undisclosed
Undisclosed
[278]
38770747 ADC 5 (DAR 2)
Undisclosed
Undisclosed
Undisclosed
[278]
38770747 ADC 6 (DAR 2)
Undisclosed
Undisclosed
Undisclosed
[278]
38770747 ADC 7 (DAR 2)
Undisclosed
Undisclosed
Undisclosed
[278]
38770747 ADC 8 (DAR 2)
Undisclosed
Undisclosed
Undisclosed
[278]
38770747 ADC 1 (DAR 4)
Undisclosed
Undisclosed
Undisclosed
[278]
38770747 ADC 2 (DAR 4)
Undisclosed
Undisclosed
Undisclosed
[278]
38770747 ADC 3 (DAR 4)
Undisclosed
Undisclosed
Undisclosed
[278]
38770747 ADC 4 (DAR 4)
Undisclosed
Undisclosed
Undisclosed
[278]
38770747 ADC 5 (DAR 4)
Undisclosed
Undisclosed
Undisclosed
[278]
38770747 ADC 6 (DAR 4)
Undisclosed
Undisclosed
Undisclosed
[278]
38770747 ADC 7 (DAR 4)
Undisclosed
Undisclosed
Undisclosed
[278]
38770747 ADC 8 (DAR 4)
Undisclosed
Undisclosed
Undisclosed
[278]
IgG-vedotin
Monomethyl auristatin E
Undisclosed
Mc-Val-Cit-PABC
[279]
40300109 ADC 2
NLRP3 Agonist 2
Undisclosed
Undisclosed
[280]
40300109 ADC 4
NLRP3 Agonist 4
Undisclosed
Mc-Val-Cit-PABC
[280]
40300109 ADC 5
NLRP3 Agonist 3
Undisclosed
Undisclosed
[280]
40300109 ADC 6
NLRP3 Agonist 3
Undisclosed
Undisclosed
[280]
40300109 ADC 7
NLRP3 Agonist 3
Undisclosed
Undisclosed
[280]
40300109 ADC 8
NLRP3 Agonist 3
Undisclosed
Undisclosed
[280]
IgG-NPLG-SN38
Active metabolite of irinotecan SN38
Undisclosed
NPLG
[281]
38679234 ADC1-FL
Fluorescein
Undisclosed
Undisclosed
[282]
38679234 ADC1-FY
Eosin Y
Undisclosed
Undisclosed
[282]
38679234 ADC1-MMAE
Monomethyl auristatin E
Undisclosed
Undisclosed
[282]
38679234 ADC1-DM1
Mertansine DM1
Undisclosed
Succinimidyl-4- (N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
[282]
38679234 ADC2
DX-8951 derivative (DXd)
DNA topoisomerase 1 (TOP1)
Mc-Gly-Gly-Phe-Gly
[282]
39424599 ADC-10B
Undisclosed
Undisclosed
Electron-deficient sulfonamide-based cleavable linker 10
[283]
39424599 ADC-S32B
Undisclosed
Undisclosed
Electron-deficient Disulfide-based cleavable linker 32
[283]
39424599 ADC-S35B
Undisclosed
Undisclosed
S35 linker
[283]
39948340 ADC 3 (nobinding)
TLR7 payload 1
Undisclosed
39948340 Linker
[284]
Isotype-MMAE (gylcan conjugation)
Monomethyl auristatin E
Undisclosed
Undisclosed
[23]
Isotype-MMAE (Lysine conjugation)
Monomethyl auristatin E
Undisclosed
Undisclosed
[23]
Control-STINGa
STINGa
Undisclosed
Undisclosed
[285]
hIgGFc-DM1 (38127423)
Mertansine DM1
Undisclosed
Undisclosed
[286]
ASAK-22
KRM-1657
Undisclosed
Mc-Val-Ala-PABC
[287]
ASAC-01
KRM-1657
Undisclosed
Undisclosed
[287]
ASAC-02
KRM-1657
Undisclosed
M6 Linker
[287]
37788373 ADC24
(R)-Budesonide
Undisclosed
MP-Ala-Ala-RG-9
[288]
hIgG-MMAE
Monomethyl auristatin E
Undisclosed
Mc-Val-Cit-PABC
[289]
mAb-ZnPcGal4 conjugate
ZnPcGal4
Undisclosed
Undisclosed
[290]
38389885 ADC 21
GRM payload (38389885)
Undisclosed
DL1 linker
[291]
38389885 ADC 22
GRM payload (38389885)
Undisclosed
DL1 linker
[291]
38389885 ADC 23
GRM payload (38389885)
Undisclosed
DL1 linker
[291]
38389885 ADC 24
GRM payload (38389885)
Undisclosed
DL1 linker
[291]
38389885 ADC 25
GRM payload (38389885)
Undisclosed
DL1 linker
[291]
38389885 ADC 26
GRM payload (38389885)
Undisclosed
DL1 linker
[291]
38389885 ADC 27
GRM payload (38389885)
Undisclosed
DL1 linker
[291]
38389885 ADC 28
GRM payload (38389885)
Undisclosed
DL1 linker
[291]
38389885 ADC 29
GRM payload (38389885)
Undisclosed
DL1 linker
[291]
38389885 ADC 30
GRM payload (38389885)
Undisclosed
DL1 linker
[291]
38389885 ADC 31
GRM payload (38389885)
Undisclosed
DL1 linker
[291]
38389885 ADC 32
GRM payload (38389885)
Undisclosed
DL1 linker
[291]
38389885 ADC 33
GRM payload (38389885)
Undisclosed
DL1 linker
[291]
38389885 ADC 34
GRM payload (38389885)
Undisclosed
DL1 linker
[291]
38389885 ADC 35
GRM payload (38389885)
Undisclosed
DL1 linker
[291]
38389885 ADC 36
GRM payload (38389885)
Undisclosed
DL1 linker
[291]
38389885 ADC 37
GRM payload (38389885)
Undisclosed
DL1 linker
[291]
38389885 ADC 38
GRM payload (38389885)
Undisclosed
DL1 linker
[291]
38389885 ADC 39
GRM payload (38389885)
Undisclosed
DL1 linker
[291]
38389885 ADC 40
GRM payload (38389885)
Undisclosed
DL1 linker
[291]
Thio-1b
Undisclosed
Undisclosed
Undisclosed
[292]
Thio-2b
Undisclosed
Undisclosed
Undisclosed
[292]
IgG IB-Y
IB-Y
Undisclosed
Undisclosed
[293]
hIgGFc-DM1 (36909522)
Mertansine DM1
Undisclosed
Undisclosed
[294]
scFv-PEG4-DM1
Mertansine DM1
Undisclosed
Undisclosed
[295]
scFv-PEG4-DM4
Mertansine DM4
Undisclosed
Undisclosed
[295]
TDC MMAE
Monomethyl auristatin E
Undisclosed
Mc-Val-Cit-PABC
[296]
ProPBD-ADC
Undisclosed
Undisclosed
Undisclosed
[297]
ADCT-241
PL2202
Undisclosed
Undisclosed
[298]
Topo1i/PARPi dual-payload ADC
Undisclosed
Undisclosed
Undisclosed
[299]
PA289 ADC
Undisclosed
Undisclosed
Undisclosed
[300]
ThiOBI ADC
Undisclosed
Undisclosed
Undisclosed
[301]
AMB304
Undisclosed
Undisclosed
Undisclosed
[302]
CAB-ADC
Undisclosed
Undisclosed
Undisclosed
[303]
DKIF976 DAC
dKIF976
Undisclosed
Undisclosed
[304]
Control-AL1- LP1
US12209180B2 P3
Undisclosed
Anti-Her2-AL1- LP1 LINKER
[305]
Control-AL1- LP2
US12209180B2 P3
Undisclosed
Anti-Her2-AL1- LP2 LINKER
[305]
Control-AL1- LP20
US12209180B2 P3
Undisclosed
Anti-Her2-AL1- LP20 LINKER
[305]
Control-AL1- LP22
US12209180B2 P3
Undisclosed
Anti-Her2-AL1- LP22 linker
[305]
Control-AL1- LP23
Undisclosed
Undisclosed
Anti-Her2-AL1- LP23 linker
[305]
Control-AL1- LP24
Undisclosed
Undisclosed
Anti-Her2-AL1- LP24 linker
[305]
Control-ALl-LP1
US12209180B2 P3
Undisclosed
Anti-Her2-AL1- LP1 LINKER
[305]
Control-AL1- LP35
Undisclosed
Undisclosed
Anti-Her2-AL1- LP35 LINKER linker
[305]
Control-AL1- LP32
Undisclosed
Undisclosed
Anti-Her2-AL1- LP32 linker
[305]
Control-AL1- LP39
Undisclosed
Undisclosed
Undisclosed
[305]
Control-AL1- LP38
Undisclosed
Undisclosed
Anti-Her2-AL1- LP38 linker
[305]
WO2024043319A1 72-1
Undisclosed
Undisclosed
Undisclosed
[306]
WO2024043319A1 72-2
Undisclosed
Undisclosed
Undisclosed
[306]
WO2024043319A1 73
Undisclosed
Undisclosed
Undisclosed
[306]
WO2024043319A1 74
WO2024043319A1 74 payload
Undisclosed
Undisclosed
[306]
WO2024043319A1 75-1
Undisclosed
Undisclosed
Undisclosed
[306]
WO2024043319A1 75-2
Undisclosed
Undisclosed
Undisclosed
[306]
WO2024043319A1 75-3
Undisclosed
Undisclosed
Undisclosed
[306]
WO2024043319A1 76
Undisclosed
Undisclosed
Undisclosed
[306]
WO2024043319A1 77
Undisclosed
Undisclosed
Undisclosed
[306]
WO2024043319A1 87
Undisclosed
Undisclosed
Undisclosed
[306]
deJ591-A
Undisclosed
Undisclosed
Undisclosed
[307]
deJ591-E
Undisclosed
Undisclosed
Undisclosed
[307]
deJ591-D
Undisclosed
Undisclosed
Undisclosed
[307]
BI2-A
Undisclosed
Undisclosed
Undisclosed
[307]
BI2-E
Undisclosed
Undisclosed
Undisclosed
[307]
BI2-D
Undisclosed
Undisclosed
Undisclosed
[307]
CN108883196A 5F9-CDA-1
Undisclosed
Undisclosed
Undisclosed
[308]
CN108883196A 5F9-CDA-2
Undisclosed
Undisclosed
Undisclosed
[308]
CN108883196A 5F9-CDA-3
Undisclosed
Undisclosed
Undisclosed
[308]
hLL2-IgG1-Tap-18Hr1
Undisclosed
Undisclosed
Undisclosed
[309]
hLL2-IgG1-Tap-18Hr2
Undisclosed
Undisclosed
Undisclosed
[309]
CN107614020A 1MB-101
Undisclosed
Undisclosed
Undisclosed
[310]
CN107614020A 1MB-102
Undisclosed
Undisclosed
Undisclosed
[310]
CN107614020A 1MB-991
Undisclosed
Undisclosed
Undisclosed
[310]
CN107614020A 1MB-992
Undisclosed
Undisclosed
Undisclosed
[310]
CN107635405A CN107635405A 19
Undisclosed
Undisclosed
Undisclosed
[311]
CN107635405A CN107635405A 20
Undisclosed
Undisclosed
Undisclosed
[311]
CN107635405A CN107635405A 21
Undisclosed
Undisclosed
Undisclosed
[311]
CN107635405A CN107635405A 22
Undisclosed
Undisclosed
Undisclosed
[311]
CN107635405A CN107635405A 23
Undisclosed
Undisclosed
Undisclosed
[311]
CN107635405A CN107635405A 24
Undisclosed
Undisclosed
Undisclosed
[311]
CN107635405A CN107635405A 25
Undisclosed
Undisclosed
Undisclosed
[311]
CN107635405A CN107635405A 26
Undisclosed
Undisclosed
Undisclosed
[311]
CN107635405A CN107635405A 27
Undisclosed
Undisclosed
Undisclosed
[311]
CN107635405A CN107635405A 28
Undisclosed
Undisclosed
Undisclosed
[311]
CN107635405A CN107635405A 29
Undisclosed
Undisclosed
Undisclosed
[311]
CN107635405A CN107635405A 30
Undisclosed
Undisclosed
Undisclosed
[311]
CN107635405A CN107635405A 31
Undisclosed
Undisclosed
Undisclosed
[311]
CN107635405A CN107635405A 32
Undisclosed
Undisclosed
Undisclosed
[311]
CN107635405A CN107635405A 33
Undisclosed
Undisclosed
Undisclosed
[311]
CN107635405A CN107635405A 34
Undisclosed
Undisclosed
Undisclosed
[311]
CN107635405A CN107635405A 35
Undisclosed
Undisclosed
Undisclosed
[311]
US20200023071A1 Example 2
US20200023071A1 Example 2 payload
Undisclosed
Undisclosed
[312]
US20200023071A1 Example 3
Undisclosed
Undisclosed
Undisclosed
[312]
anti-PanP-DM1
Undisclosed
Undisclosed
Undisclosed
[313]
BCN-B12 B12-v1a-145
Undisclosed
Undisclosed
linker145
[314]
WO2019126691A1 Conjugate No.138
Conjugate No.138 Payload
Undisclosed
Conjugate No.138 Linker
[315]
WO2019126691A1 Conjugate No.139
undisclosed
Undisclosed
Conjugate No.138 Linker
[315]
WO2019126691A1 Conjugate No.140
Conjugate No.140 Payload
Undisclosed
Conjugate No.138 Linker
[315]
WO2019126691A1 Conjugate No.141
Conjugate No.141 Payload
Undisclosed
Conjugate No.138 Linker
[315]
WO2019126691A1 Conjugate No.142
Conjugate No.136 Payload
Undisclosed
Conjugate No.57 Linker
[315]
WO2019126691A1 Conjugate No.143
Conjugate No.136 Payload
Undisclosed
Conjugate No.71 Linker
[315]
WO2019126691A1 Conjugate No.144
Conjugate No.136 Payload
Undisclosed
Conjugate No.67 Linker
[315]
WO2019126691A1 Conjugate No.145
Conjugate No.136 Payload
Undisclosed
Conjugate No.73 Linker
[315]
WO2019126691A1 Conjugate No.146
Conjugate No.136 Payload
Undisclosed
DL18 linker
[315]
WO2019126691A1 Conjugate No.147
Conjugate No.94 Payload
Undisclosed
Conjugate No.147 Linker
[315]
WO2019126691A1 Conjugate No.148
Conjugate No.148 Payload
Undisclosed
Conjugate No.147 Linker
[315]
WO2019126691A1 Conjugate No.149
Conjugate No.94 Payload
Undisclosed
Conjugate No.147 Linker
[315]
WO2019126691A1 Conjugate No.150
Conjugate No.112 Payload
Undisclosed
Conjugate No.112 Linker
[315]
WO2019126691A1 Conjugate No.151
Conjugate No.112 Payload
Undisclosed
Conjugate No.151 Linker
[315]
WO2019126691A1 Conjugate No.152
Conjugate No.94 Payload
Undisclosed
Conjugate No.152 Linker
[315]
WO2019126691A1 Conjugate No.153
Conjugate No.94 Payload
Undisclosed
Conjugate No.119 Linker
[315]
WO2019126691A1 Conjugate No.154
Conjugate No.137 Payload
Undisclosed
Conjugate No.105 Linker
[315]
WO2019126691A1 Conjugate No.155
Conjugate No.155 Payload
Undisclosed
Conjugate No.105 Linker
[315]
WO2019126691A1 Conjugate No.156
Conjugate No.156 Payload
Undisclosed
Conjugate No.105 Linker
[315]
WO2019126691A1 Conjugate No.157
Conjugate No.157 Payload
Undisclosed
Conjugate No.105 Linker
[315]
WO2019126691A1 Conjugate No.158
Conjugate No.158 Payload
Undisclosed
Conjugate No.94 Linker
[315]
WO2019126691A1 Conjugate No.159
Conjugate No.159 Payload
Undisclosed
Conjugate No.94 Linker
[315]
WO2019126691A1 Conjugate No.160
Conjugate No.160 Payload
Undisclosed
Conjugate No.105 Linker
[315]
WO2019126691A1 Conjugate No.161
Conjugate No.161 Payload
Undisclosed
Conjugate No.105 Linker
[315]
WO2019126691A1 Conjugate No.162
Conjugate No.162 Payload
Undisclosed
Conjugate No.105 Linker
[315]
WO2019126691A1 Conjugate No.163
Conjugate No.163 Payload
Undisclosed
Conjugate No.105 Linker
[315]
WO2019126691A1 Conjugate No.164
Conjugate No.164 Payload
Undisclosed
Conjugate No.105 Linker
[315]
WO2019126691A1 Conjugate No.165
Conjugate No.165 Payload
Undisclosed
Conjugate No.105 Linker
[315]
WO2019126691A1 Conjugate No.166
Conjugate No.166 Payload
Undisclosed
Conjugate No.105 Linker
[315]
WO2019126691A1 Conjugate No.167
Conjugate No.167 Payload
Undisclosed
Conjugate No.167 Linker
[315]
WO2019126691A1 Conjugate No.168
Conjugate No.168 Payload
Undisclosed
Conjugate No.105 Linker
[315]
WO2019126691A1 Conjugate No.169
Conjugate No.169 Payload
Undisclosed
Conjugate No.105 Linker
[315]
WO2019126691A1 Conjugate No.170
Conjugate No.170 Payload
Undisclosed
Conjugate No.167 Linker
[315]
WO2019126691A1 Conjugate No.171
Conjugate No.171 Payload
Undisclosed
Conjugate No.105 Linker
[315]
WO2019126691A1 Conjugate No.172
Conjugate No.172 Payload
Undisclosed
Conjugate No.105 Linker
[315]
WO2019126691A1 Conjugate No.173
Conjugate No.173 Payload
Undisclosed
Conjugate No.105 Linker
[315]
WO2019126691A1 Conjugate No.174
Conjugate No.174 Payload
Undisclosed
Conjugate No.105 Linker
[315]
WO2019126691A1 Conjugate No.175
Conjugate No.175 Payload
Undisclosed
Conjugate No.105 Linker
[315]
WO2019126691A1 Conjugate No.176
Conjugate No.176 Payload
Undisclosed
Conjugate No.105 Linker
[315]
WO2019126691A1 Conjugate No.177
Conjugate No.177 Payload
Undisclosed
Conjugate No.105 Linker
[315]
WO2024138000A1 FelD1 Ab
Undisclosed
Undisclosed
Undisclosed
[316]
FelD1- (AL11a)4
Undisclosed
Undisclosed
Undisclosed
[316]
FelD1- (AL2a)4
Undisclosed
Undisclosed
Undisclosed
[316]
FelD1- (AL3a)4
Undisclosed
Undisclosed
Undisclosed
[316]
FelD1- (AL7)4
Undisclosed
Undisclosed
Undisclosed
[316]
FelD1- (BL1)3.9
Undisclosed
Undisclosed
Undisclosed
[316]
FelD1- (BL3b)3.8
Undisclosed
Undisclosed
Undisclosed
[316]
FelD1- (AL7-LP1)3.9
aHer2- (AL6-LP1)<sub>3.6</sub> Payload
Undisclosed
aHer2- (AL7-LP1)<sub>3.7</sub> Linker
[316]
FelD1- (AL7-LP13)7.3
aHer2- (AL6-LP1)<sub>3.6</sub> Payload
Undisclosed
aHer2- (AL7-LP13)<sub>7.3</sub> Linker
[316]
FelD1- (AL7-LP2)3.80
aHer2- (AL7-LP2)<sub>3.83</sub> Payload
Undisclosed
aHer2- (AL7-LP2)<sub>3.83</sub> Linker
[316]
FelD1- (AL7-LP3)3.82
DX-8951 derivative (DXd)
DNA topoisomerase 1 (TOP1)
aHer2- (AL7-LP2)<sub>3.83</sub> Linker
[316]
FelD1- (AL7-LP4)3.82
DX-8951 derivative (DXd)
DNA topoisomerase 1 (TOP1)
aHer2- (AL7-LP2)<sub>3.83</sub> Linker
[316]
FelD1- (AL7-LP5)3.69
aHer2- (AL7-LP5)<sub>3.80</sub> Payload
Undisclosed
aHer2- (AL7-LP5)<sub>3.80</sub> Linker
[316]
FelD1- (AL7-LP7)3.68
aHer2- (AL7-LP7)<sub>3.70</sub> Payload
Undisclosed
aHer2- (AL7-LP2)<sub>3.83</sub> Linker
[316]
FelD1- (AL7-LP9)3.89
undisclosed
Undisclosed
aHer2- (AL7-LP2)<sub>3.83</sub> Linker
[316]
FelD1- (AL7-LP12)3.83
aHer2- (AL7-LP12)<sub>3.82</sub> Payload
Undisclosed
aHer2- (AL7-LP12)<sub>3.82</sub> Linker
[316]
FelD1- (AL4c-LP1B)3.45
aHer2- (AL4c-LP1B)<sub>3.49</sub> Payload
Undisclosed
aHer2- (AL4c-LP1B)<sub>3.49</sub> Linker
[316]
FelD1- (AL11a-LP1)4
aHer2- (AL6-LP1)<sub>3.6</sub> Payload
Undisclosed
aHer2- (AL7-LP2)<sub>3.83</sub> Linker
[316]
FelD1- (AL11a-LP13)7.3
aHer2- (AL6-LP1)<sub>3.6</sub> Payload
Undisclosed
aHer2- (AL11a-LP13)<sub>7.8</sub> Linker
[316]
FelD1- (AL11a-LP15)7.0
DX-8951 derivative (DXd)
DNA topoisomerase 1 (TOP1)
aHer2- (AL11a-LP15)<sub>7.6</sub> Linker
[316]
FelD1- (BL1-LP1)7.6
aHer2- (AL6-LP1)<sub>3.6</sub> Payload
Undisclosed
aHer2- (BL1-LP1)<sub>7.7</sub> Linker
[316]
FelD1- (BL1-LP13)15.00
aHer2- (AL6-LP1)<sub>3.6</sub> Payload
Undisclosed
aHer2- (BL1-LP13)<sub>14.88</sub> Linker
[316]
FelD1- (BL3b-LP1)7.1
aHer2- (AL4c-LP1B)<sub>3.49</sub> Payload
Undisclosed
aHer2- (BL3b-LP1)<sub>7.5</sub> Linker
[316]
FelD1 1- (Mc-GGFG-DXD)7.5
DX-8951 derivative (DXd)
DNA topoisomerase 1 (TOP1)
Mc-Gly-Gly-Phe-Gly
[316]
FelD1 2- (Mc-GGFG-DXD)7.5
DX-8951 derivative (DXd)
DNA topoisomerase 1 (TOP1)
Mc-Gly-Gly-Phe-Gly
[316]
FelD1 3- (Mc-GGFG-DXD)7.5
DX-8951 derivative (DXd)
DNA topoisomerase 1 (TOP1)
Mc-Gly-Gly-Phe-Gly
[316]
FelD1 1- (Mc-GGFG-DXD)7.0
DX-8951 derivative (DXd)
DNA topoisomerase 1 (TOP1)
Mc-Gly-Gly-Phe-Gly
[316]
FelD1 2- (Mc-GGFG-DXD)7.0
DX-8951 derivative (DXd)
DNA topoisomerase 1 (TOP1)
Mc-Gly-Gly-Phe-Gly
[316]
FelD1 3- (Mc-GGFG-DXD)7.0
DX-8951 derivative (DXd)
DNA topoisomerase 1 (TOP1)
Mc-Gly-Gly-Phe-Gly
[316]
US20230022596A1 B-1
B-1 Payload
Undisclosed
B-1 Linker
[317]
US20230022596A1 B-2
B-2 Payload
Undisclosed
B-1 Linker
[317]
US20230022596A1 B-3
B-3 Payload
Undisclosed
B-1 Linker
[317]
US20230022596A1 B-4
B-4 Payload
Undisclosed
B-1 Linker
[317]
US20230022596A1 B-5
B-5 Payload
Undisclosed
B-1 Linker
[317]
US20230022596A1 B-6
B-6 Payload
Undisclosed
B-1 Linker
[317]
US20230022596A1 B-7
B-7 Payload
Undisclosed
B-1 Linker
[317]
US20230022596A1 B-8
B-8 Payload
Undisclosed
B-1 Linker
[317]
US20230022596A1 B-9
B-1 Payload
Undisclosed
B-9 Linker
[317]
US20230022596A1 B-10
B-2 Payload
Undisclosed
B-9 Linker
[317]
US20230022596A1 B-11
B-3 Payload
Undisclosed
B-9 Linker
[317]
US20230022596A1 B-12
B-4 Payload
Undisclosed
B-9 Linker
[317]
US20230022596A1 B-13
B-5 Payload
Undisclosed
B-9 Linker
[317]
US20230022596A1 B-14
B-6 Payload
Undisclosed
B-9 Linker
[317]
US20230022596A1 B-15
B-7 Payload
Undisclosed
B-9 Linker
[317]
US20230022596A1 B-16
B-8 Payload
Undisclosed
B-9 Linker
[317]
US20230022596A1 B-17
B-1 Payload
Undisclosed
B-17 Linker
[317]
US20230022596A1 B-18
B-2 Payload
Undisclosed
B-17 Linker
[317]
US20230022596A1 B-19
B-3 Payload
Undisclosed
B-17 Linker
[317]
US20230022596A1 B-20
B-4 Payload
Undisclosed
B-17 Linker
[317]
US20230022596A1 B-21
B-5 Payload
Undisclosed
B-17 Linker
[317]
US20230022596A1 B-22
B-6 Payload
Undisclosed
B-17 Linker
[317]
US20230022596A1 B-23
B-7 Payload
Undisclosed
B-17 Linker
[317]
US20230022596A1 B-24
B-8 Payload
Undisclosed
B-17 Linker
[317]
US20230022596A1 B-25
B-1 Payload
Undisclosed
B-25 Linker
[317]
US20230022596A1 B-26
B-2 Payload
Undisclosed
B-25 Linker
[317]
US20230022596A1 B-27
B-3 Payload
Undisclosed
B-25 Linker
[317]
US20230022596A1 B-28
B-4 Payload
Undisclosed
B-25 Linker
[317]
US20230022596A1 B-29
B-5 Payload
Undisclosed
B-25 Linker
[317]
US20230022596A1 B-30
B-6 Payload
Undisclosed
B-25 Linker
[317]
US20230022596A1 B-31
B-7 Payload
Undisclosed
B-25 Linker
[317]
US20230022596A1 B-32
B-7 Payload
Undisclosed
B-25 Linker
[317]
US20230022596A1 B-33
B-1 Payload
Undisclosed
B-33 Linker
[317]
US20230022596A1 B-34
B-2 Payload
Undisclosed
B-33 Linker
[317]
US20230022596A1 B-35
B-3 Payload
Undisclosed
B-33 Linker
[317]
US20230022596A1 B-36
B-4 Payload
Undisclosed
B-33 Linker
[317]
US20230022596A1 B-37
B-5 Payload
Undisclosed
B-33 Linker
[317]
US20230022596A1 B-38
B-6 Payload
Undisclosed
B-33 Linker
[317]
US20230022596A1 B-39
B-7 Payload
Undisclosed
B-33 Linker
[317]
US20230022596A1 B-40
B-8 Payload
Undisclosed
B-33 Linker
[317]
US20230022596A1 B-41
B-1 Payload
Undisclosed
B-33 Linker
[317]
US20230022596A1 B-42
B-2 Payload
Undisclosed
B-33 Linker
[317]
US20230022596A1 B-43
B-3 Payload
Undisclosed
B-33 Linker
[317]
US20230022596A1 B-44
B-4 Payload
Undisclosed
B-33 Linker
[317]
US20230022596A1 B-45
B-5 Payload
Undisclosed
B-33 Linker
[317]
US20230022596A1 B-46
B-6 Payload
Undisclosed
B-33 Linker
[317]
US20230022596A1 B-47
B-7 Payload
Undisclosed
B-33 Linker
[317]
US20230022596A1 B-48
B-8 Payload
Undisclosed
B-33 Linker
[317]
US20230022596A1 B-49
B-1 Payload
Undisclosed
B-49 Linker
[317]
US20230022596A1 B-50
B-2 Payload
Undisclosed
B-49 Linker
[317]
US20230022596A1 B-51
B-3 Payload
Undisclosed
B-49 Linker
[317]
US20230022596A1 B-52
B-4 Payload
Undisclosed
B-49 Linker
[317]
US20230022596A1 B-53
B-5 Payload
Undisclosed
B-49 Linker
[317]
US20230022596A1 B-54
B-6 Payload
Undisclosed
B-49 Linker
[317]
US20230022596A1 B-55
B-7 Payload
Undisclosed
B-49 Linker
[317]
US20230022596A1 B-56
B-8 Payload
Undisclosed
B-49 Linker
[317]
US20230022596A1 B-57
B-1 Payload
Undisclosed
B-57 Linker
[317]
US20230022596A1 B-58
B-2 Payload
Undisclosed
B-57 Linker
[317]
US20230022596A1 B-59
B-3 Payload
Undisclosed
B-57 Linker
[317]
US20230022596A1 B-60
B-4 Payload
Undisclosed
B-57 Linker
[317]
US20230022596A1 B-61
B-5 Payload
Undisclosed
B-57 Linker
[317]
US20230022596A1 B-62
B-6 Payload
Undisclosed
B-57 Linker
[317]
US20230022596A1 B-63
B-7 Payload
Undisclosed
B-57 Linker
[317]
US20230022596A1 B-64
B-8 Payload
Undisclosed
B-57 Linker
[317]
T-1-AB
T-1-AB Payload
Undisclosed
T-1-AB Linker
[318]
T-3-AB 0.5
T-3-AB Payload
Undisclosed
T-3-AB Linker
[318]
T-4-AB 0.42
T-4-AB Payload
Undisclosed
T-4-AB Linker
[318]
AU2023281032A1 ADC-1
Monomethyl auristatin E
Microtubule (MT)
AU2023281032A1 ADC-1 linker
[319]
IgG-P1-L12-P4
P4 payload
Undisclosed
L12 linker
[320]
mT-GGFG- Compound 104
TW202426058A+MT-GGFG-Compound 104+payload
Undisclosed
Undisclosed
[323]
mT-GGFG- Compound 108
TW202426058A+MT-GGFG-Compound 108+payload
Undisclosed
Undisclosed
[323]
mT-GGFG- Compound 127
TW202426058A+MT-GGFG-Compound 127+payload
Undisclosed
Undisclosed
[323]
mT-GGFG-AM-Compound136
TW202426058A+MT-AM-GGFG-Compound 136+payload
Undisclosed
TW202426058A+MT-AM-GGFG-Compound 136+Linker
[323]
mT-GGFG-AM-Compound139
TW202426058A+MT-AM-GGFG-Compound 136+payload
Undisclosed
TW202426058A+MT-AM-GGFG-Compound 139+Linker
[323]
mT-GGFG-AM-Compound129
TW202426058A+MT-AM-GGFG-Compound 129+payload
Undisclosed
CN115160403A+B17+Linker
[323]
mT-GGFG-AM-Compound113
TW202426058A+MT-AM-GGFG-Compound 113+payload
Undisclosed
Undisclosed
[323]
mT-GGFG-AM-Compound141
TW202426058A+MT-AM-GGFG-Compound 141+payload
Undisclosed
Undisclosed
[323]
mC-GGFG-AM-Compound141
TW202426058A+MC-GGFG-AM-Compound141+payload
Undisclosed
Mc-Gly-Gly-Phe-Gly
[323]
mT-GGFG-AM-Compound117
TW202426058A+MC-GGFG-AM-Compound117+payload
Undisclosed
TW202426058A+MT-GGFG-AM-Compound117+Linker
[323]
mT-GGFG-AM-Compound118
TW202426058A+MT-GGFG-AM-Compound118+payload
Undisclosed
TW202426058A+MT-GGFG-AM-Compound118+Linker
[323]
mC-GGFG-AM-Compound139
TW202426058A+MC-GGFG-AM-Compound139+payload
Undisclosed
Mc-Gly-Gly-Phe-Gly
[323]
mT-GGFG-Compound140
10NH2-11F-Camptothecin
DNA topoisomerase I (TOP1)
CN115160403A+B17+Linker
[323]
mT-GGFG-Compound141
FD5
DNA topoisomerase I (TOP1)
CN115160403A+B17+Linker
[323]
mT-GGFG-Compound145
FD5
DNA topoisomerase I (TOP1)
CN115160403A+B17+Linker
[323]
mT-GGFG-Compound148
FD7
DNA topoisomerase I (TOP1)
CN115160403A+B17+Linker
[323]
mC-GGFG-Compound140
TW202426058A+MC-GGFG-Compound140+payload
Undisclosed
Mc-Gly-Gly-Phe-Gly
[323]
mT-GGFG-Compound142
TW202426058A+MT-GGFG-Compound142+payload
Undisclosed
CN115160403A+B17+Linker
[323]
mC-GGFG-Compound141
TW202426058A+MC-GGFG-Compound141+payload
Undisclosed
Mc-Gly-Gly-Phe-Gly
[323]
wO2024133815A1 Structure (4)
WO2024133815A1+structure (4)+payload
Undisclosed
WO2024133815A1+structure (4)+Linker
[324]
cN118878620A ADC Drug linker 1
CN118878620A+Drug linker 1+payload
Undisclosed
CN118878620A+Drug linker 1+Linker
[325]
cN118878620A ADC Drug linker 2
CN118878620A+Drug linker 2+payload
Undisclosed
CN118878620A+Drug linker 2+Linker
[325]
cN118878620A ADC Drug linker 3
CN118878620A+Drug linker 3+payload
Undisclosed
CN118878620A+Drug linker 1+Linker
[325]
cN118878620A ADC Drug linker 4
CN118878620A+Drug linker 4+payload
Undisclosed
CN118878620A+Drug linker 1+Linker
[325]
cN118878620A ADC Drug linker 5
CN118878620A+Drug linker 5+payload
Undisclosed
CN118878620A+Drug linker 5+Linker
[325]
cN118878620A ADC Drug linker 6
CN118878620A+Drug linker 5+payload
Undisclosed
CN118878620A+Drug linker 6+Linker
[325]
cN118878620A ADC Drug linker 7
CN118878620A+Drug linker 7+payload
Undisclosed
CN118878620A+Drug linker 7+Linker
[325]
cN118878620A ADC Drug linker 8
CN118878620A+Drug linker 8+payload
Undisclosed
CN118878620A+Drug linker 8+Linker
[325]
cN118878620A ADC Drug linker 9
CN118878620A+Drug linker 9+payload
Undisclosed
CN118878620A+Drug linker 7+Linker
[325]
cN118878620A ADC Drug linker 10
CN118878620A+Drug linker 9+payload
Undisclosed
CN118878620A+Drug linker 10+Linker
[325]
cN118878620A ADC Drug linker 11
CN118878620A+Drug linker 9+payload
Undisclosed
CN118878620A+Drug linker 11+Linker
[325]
cN118878620A ADC Drug linker 12
CN118878620A+Drug linker 9+payload
Undisclosed
CN118878620A+Drug linker 12+Linker
[325]
cN118878620A ADC Drug linker 13
CN118878620A+Drug linker 9+payload
Undisclosed
CN118878620A+Drug linker 11+Linker
[325]
cN118878620A ADC Drug linker 14
CN118878620A+Drug linker 14+payload
Undisclosed
CN118878620A+Drug linker 14+Linker
[325]
cN118878620A ADC Drug linker 16
CN118878620A+Drug linker 16+payload
Undisclosed
Undisclosed
[325]
cN118878620A ADC Drug linker 15
CN118878620A+Drug linker 14+payload
Undisclosed
CN118878620A+Drug linker 11+Linker
[325]
cN118878620A ADC Drug linker 17
CN118878620A+Drug linker 17+payload
Undisclosed
CN118878620A+Drug linker 1+Linker
[325]
cN118878620A ADC Drug linker 18
CN118878620A+Drug linker 18+payload
Undisclosed
CN118878620A+Drug linker 1+Linker
[325]
cN118878620A ADC Drug linker 19
CN118878620A+Drug linker 19+payload
Undisclosed
CN118878620A+Drug linker 19+Linker
[325]
cN118878620A ADC Drug linker 20
CN118878620A+Drug linker 20+payload
Undisclosed
CN118878620A+Drug linker 1+Linker
[325]
cN118878620A ADC Drug linker 21
CN118878620A+Drug linker 21+payload
Undisclosed
CN118878620A+Drug linker 1+Linker
[325]
cN118878620A ADC Drug linker 22
CN118878620A+Drug linker 22+payload
Undisclosed
CN118878620A+Drug linker 1+Linker
[325]
cN118878620A ADC Drug linker 23
CN118878620A+Drug linker 23+payload
Undisclosed
Mc-Gly-Gly-Phe-Gly
[325]
cN118878620A ADC Drug linker 24
CN118878620A+Drug linker 24+payload
Undisclosed
CN118878620A+Drug linker 1+Linker
[325]
cN118878620A ADC Drug linker 25
CN118878620A+Drug linker 25+payload
Undisclosed
CN118878620A+Drug linker 1+Linker
[325]
cN118878620A ADC Drug linker 26
CN118878620A+Drug linker 26+payload
Undisclosed
CN118878620A+Drug linker 1+Linker
[325]
wO2022197877A1 compound 4
WO2022197877A1+compound 4+payload
Undisclosed
WO2022197877A1+compound 4+Linker
[327]
wO2022197877A1 compound 5
WO2022197877A1+compound 5+payload
Undisclosed
WO2022197877A1+compound 4+Linker
[327]
wO2022197877A1 compound 6
WO2022197877A1+compound 6+payload
Undisclosed
WO2022197877A1+compound 6+Linker
[327]
wO2022197877A1 compound 7
WO2022197877A1+compound 7+payload
Undisclosed
WO2022197877A1+compound 6+Linker
[327]
synthesis Example 2
WO2022197877A1+Synthesis Example 2+payload
Undisclosed
Mc-Val-Cit-PABC
[327]
wO2022197877A1 compound 3
WO2022197877A1+compound 3+payload
Undisclosed
Mc-Val-Cit-PABC
[327]
wO2022197877A1 compound 10
WO2022197877A1+compound 10+payload
Undisclosed
WO2022197877A1+compound 10+Linker
[327]
wO2022197877A1 compound 8
WO2022197877A1+compound 8+payload
Undisclosed
WO2022197877A1+compound 10+Linker
[327]
wO2022197877A1 compound 9
WO2022197877A1+compound 9+payload
Undisclosed
WO2022197877A1+compound 10+Linker
[327]
cN119072334A Formula 6
CN119072334A+Formula 6+payload
Undisclosed
Undisclosed
[328]
cN119072334A Formula 7
CN119072334A+Formula 7+payload
Undisclosed
CN119072334A+Formula 7+Linker
[328]
cN119072334A Formula 8
Topo1 inhibitor H
DNA topoisomerase I (TOP1)
CN119072334A+Formula 8+Linker
[328]
mC-VaI-Cit-PAB-MMAE
Undisclosed
Undisclosed
CN119072334A+MC-VaI-Cit-PAB-MMAE+Linker
[328]
thioBridge-Glu- (Val-Cit-PAB-MMáE)-PEG (24u)
CN119072334A+ThioBridge&#9322;-Glu- (Val-Cit-PAB-MM&aacute;E)-PEG (24u)+payload
Undisclosed
CN119072334A+ThioBridge&#9322;-Glu- (Val-Cit-PAB-MM&aacute;E)-PEG (24u)+Linker
[328]
thioBridge-Glu-[ (Val-Cit-PAB-MMáE)]2-Glu-[PEG (24u)]2
Topo1 inhibitor H
DNA topoisomerase I (TOP1)
CN119072334A+ThioBridge&#9322;-Glu-[ (Val-Cit-PAB-MM&aacute;E)]2-Glu-[PEG (24u)]2+Linker
[328]
uS20240148883A1 Compound 18- Target 1
Undisclosed
Undisclosed
Undisclosed
[329]
uS20240148883A1 Compound 18- Target 2
Undisclosed
Undisclosed
Undisclosed
[329]
uS20240148883A1 Compound 18- Target 3
Undisclosed
Undisclosed
Undisclosed
[329]
uS20240148883A1 Compound 18- Target 4
Undisclosed
Undisclosed
Undisclosed
[329]
uS20240148883A1 Compound 18- Target 5
Undisclosed
Undisclosed
Undisclosed
[329]
uS20240148883A1 Compound 18- Target 6
Undisclosed
Undisclosed
Undisclosed
[329]
uS20240148883A1 Compound 18- Target 7
Undisclosed
Undisclosed
Undisclosed
[329]
uS20240148883A1 Compound 18- Target 8
Undisclosed
Undisclosed
Undisclosed
[329]
uS20240148883A1 Compound 18- Target 9
Undisclosed
Undisclosed
Undisclosed
[329]
uS20240148883A1 Compound 18- Target 10
Undisclosed
Undisclosed
Undisclosed
[329]
uS20240148883A1 Compound 36- Target 1
Undisclosed
Undisclosed
Undisclosed
[329]
uS20240148883A1 Compound 36- Target 2
Undisclosed
Undisclosed
Undisclosed
[329]
uS20240148883A1 Compound 36- Target 3
Undisclosed
Undisclosed
Undisclosed
[329]
uS20240148883A1 Compound 36- Target 4
Undisclosed
Undisclosed
Undisclosed
[329]
uS20240148883A1 Compound 36- Target 5
Undisclosed
Undisclosed
Undisclosed
[329]
uS20240148883A1 Compound 36- Target 6
Undisclosed
Undisclosed
Undisclosed
[329]
uS20240148883A1 Compound 36- Target 7
Undisclosed
Undisclosed
Undisclosed
[329]
uS20240148883A1 Compound 36- Target 8
Undisclosed
Undisclosed
Undisclosed
[329]
uS20240148883A1 Compound 36- Target 9
Undisclosed
Undisclosed
Undisclosed
[329]
uS20240148883A1 Compound 36- Target 10
Undisclosed
Undisclosed
Undisclosed
[329]
uS20240148883A1 Compound 32- Target 1
Undisclosed
Undisclosed
Undisclosed
[329]
uS20240148883A1 Compound 32- Target 2
Undisclosed
Undisclosed
Undisclosed
[329]
uS20240148883A1 Compound 32- Target 3
Undisclosed
Undisclosed
Undisclosed
[329]
uS20240148883A1 Compound 32- Target 4
Undisclosed
Undisclosed
Undisclosed
[329]
uS20240148883A1 Compound 32- Target 5
Undisclosed
Undisclosed
Undisclosed
[329]
uS20240148883A1 Compound 32- Target 6
Undisclosed
Undisclosed
Undisclosed
[329]
uS20240148883A1 Compound 32- Target 7
Undisclosed
Undisclosed
Undisclosed
[329]
uS20240148883A1 Compound 32- Target 8
Undisclosed
Undisclosed
Undisclosed
[329]
uS20240148883A1 Compound 32- Target 9
Undisclosed
Undisclosed
Undisclosed
[329]
uS20240148883A1 Compound 32- Target 10
Undisclosed
Undisclosed
Undisclosed
[329]
cN118043080A ADC-4
CN118043080A+ADC-4+payload
Undisclosed
CN118043080A+ADC-4+Linker
[330]
cN118043080A ADC-5
CN118043080A+ADC-5+payload
Undisclosed
CN118043080A+ADC-5+Linker
[330]
cN118043080A ADC-6
CN118043080A+ADC-6+payload
Undisclosed
CN118043080A+ADC-6+Linker
[330]
wO2024099368A1 Tra-CAST-MMAE
Monomethyl auristatin E
Microtubule (MT)
WO2024099368A1+Tra-CAST-MMAE+Linker
[331]
cN110845480B ADC1
CN110845480B+ADC1+payload
Undisclosed
CN110845480B+ADC1+Linker
[333]
cN110845480B ADC2
CN110845480B+ADC2+payload
Undisclosed
CN110845480B+ADC1+Linker
[333]
cN110845480B ADC3
CN110845480B+ADC3+payload
Undisclosed
CN110845480B+ADC3+Linker
[333]
cN110845480B ADC4
CN110845480B+ADC4+payload
Undisclosed
CN110845480B+ADC4+Linker
[333]
jP2024533562A ADC-1
JP2024533562A ADC-9 payload
Undisclosed
Mc-Val-Cit-PABC
[335]
jP2024533562A ADC-2
JP2024533562A ADC-10 payload
Undisclosed
Mc-Val-Cit-PABC
[335]
jP2024533562A ADC-3
JP2024533562A ADC-11 payload
Undisclosed
Mc-Val-Cit-PABC
[335]
jP2024533562A ADC-4
EP4494658A1 antibody-drug conjugate 1 payload
DNA topoisomerase I (TOP1)
Mc-Val-Cit-PABC
[335]
jP2024533562A ADC-5
JP2024533562A ADC-13 payload
Undisclosed
Mc-Val-Cit-PABC
[335]
jP2024533562A ADC-6
JP2024533562A ADC-14 payload
Undisclosed
Mc-Val-Cit-PABC
[335]
jP2024533562A ADC-7
JP2024533562A ADC-15 payload
Undisclosed
Mc-Val-Cit-PABC
[335]
jP2024533562A ADC-8
JP2024533562A ADC-16 payload
Undisclosed
Mc-Val-Cit-PABC
[335]
jP2024533562A ADC-9
JP2024533562A ADC-9 payload
Undisclosed
JP2024533562A ADC-16 linker
[335]
jP2024533562A ADC-10
JP2024533562A ADC-10 payload
Undisclosed
JP2024533562A ADC-16 linker
[335]
jP2024533562A ADC-11
JP2024533562A ADC-11 payload
Undisclosed
JP2024533562A ADC-16 linker
[335]
jP2024533562A ADC-12
EP4494658A1 antibody-drug conjugate 1 payload
DNA topoisomerase I (TOP1)
JP2024533562A ADC-16 linker
[335]
jP2024533562A ADC-13
JP2024533562A ADC-13 payload
Undisclosed
JP2024533562A ADC-16 linker
[335]
jP2024533562A ADC-14
JP2024533562A ADC-14 payload
Undisclosed
JP2024533562A ADC-16 linker
[335]
jP2024533562A ADC-15
JP2024533562A ADC-15 payload
Undisclosed
JP2024533562A ADC-16 linker
[335]
jP2024533562A ADC-16
JP2024533562A ADC-16 payload
Undisclosed
JP2024533562A ADC-16 linker
[335]
jP2024533562A ADC-17
Undisclosed
Undisclosed
Undisclosed
[335]
ab-TfR2-CIDE-BRM1-9
Undisclosed
Undisclosed
Undisclosed
ab-TfR2-CIDE-BRM1-20
Undisclosed
Undisclosed
Undisclosed
ab-TfR2-CIDE-BRM1-19
Undisclosed
Undisclosed
Undisclosed
ab-TfR2-CIDE-BRM1-15
Undisclosed
Undisclosed
Undisclosed
ab-TfR2-CIDE-BRM1-13
Undisclosed
Undisclosed
Undisclosed
wO2023173132A1 ADC-12
P9
Undisclosed
Undisclosed
[37]
wO2023173132A1 ADC-13
P9
Undisclosed
Undisclosed
[37]
wO2023173132A1ADC-14
P9
Undisclosed
Undisclosed
[37]
wO2024078586A9 ADC A-01
Undisclosed
Undisclosed
Undisclosed
[336]
wO2024078586A9 ADC A-02
Undisclosed
Undisclosed
Undisclosed
[336]
wO2024078586A9 ADC A-03
Undisclosed
Undisclosed
Undisclosed
[336]
wO2024078586A9 ADC A-04
Undisclosed
Undisclosed
Undisclosed
[336]
wO2024078586A9 ADC A-05
Undisclosed
Undisclosed
Undisclosed
[336]
wO2024078586A9 ADC A-06
Undisclosed
Undisclosed
Undisclosed
[336]
wO2024078586A9 ADC A-07
Undisclosed
Undisclosed
Undisclosed
[336]
wO2024078586A9 ADC A-08
Undisclosed
Undisclosed
Undisclosed
[336]
wO2024078586A9 ADC A-09
Undisclosed
Undisclosed
Undisclosed
[336]
wO2024078586A9 ADC A-10
Undisclosed
Undisclosed
Undisclosed
[336]
wO2024078586A9 ADC A-11
Undisclosed
Undisclosed
Undisclosed
[336]
wO2024078586A9 ADC A-12
Undisclosed
Undisclosed
Undisclosed
[336]
wO2024078586A9 ADC A-13
Undisclosed
Undisclosed
Undisclosed
[336]
wO2024078586A9 ADC A-14
Undisclosed
Undisclosed
Undisclosed
[336]
wO2024078586A9 ADC A-15
Undisclosed
Undisclosed
Undisclosed
[336]
wO2024078586A9 ADC A-16
Undisclosed
Undisclosed
Undisclosed
[336]
wO2024078586A9 ADC A-17
Undisclosed
Undisclosed
Undisclosed
[336]
wO2024078586A9 ADC A-18
Undisclosed
Undisclosed
Undisclosed
[336]
wO2024078586A9 ADC A-19
Undisclosed
Undisclosed
Undisclosed
[336]
wO2024078586A9 ADC A-20
Undisclosed
Undisclosed
Undisclosed
[336]
wO2024078586A9 ADC A-21
Undisclosed
Undisclosed
Undisclosed
[336]
wO2024078586A9 ADC A-22
Undisclosed
Undisclosed
Undisclosed
[336]
wO2024078586A9 ADC A-23
Undisclosed
Undisclosed
Undisclosed
[336]
wO2024078586A9 ADC A-24
Undisclosed
Undisclosed
Undisclosed
[336]
wO2024078586A9 ADC A-25
Undisclosed
Undisclosed
Undisclosed
[336]
wO2024078586A9 ADC A-26
undisclosed
Undisclosed
Undisclosed
[336]
wO2024078586A9 ADC-B-01
undisclosed
Undisclosed
Undisclosed
[336]
wO2024078586A9 ADC-B-02
Undisclosed
Undisclosed
Undisclosed
[336]
wO2024078586A9 ADC-B-03
Undisclosed
Undisclosed
Undisclosed
[336]
wO2024078586A9 ADC-B-04
undisclosed
Undisclosed
Undisclosed
[336]
wO2024078586A9 ADC-B-05
undisclosed
Undisclosed
Undisclosed
[336]
wO2024078586A9 ADC-B-06
undisclosed
Undisclosed
Undisclosed
[336]
wO2024078586A9 ADC-C-01
undisclosed
Undisclosed
Undisclosed
[336]
wO2024083953A1 Formula1
undisclosed
Undisclosed
Undisclosed
[337]
wO2024083953A1 Formula2
undisclosed
Undisclosed
Undisclosed
[337]
wO2024083953A1 Formula3
undisclosed
Undisclosed
Undisclosed
[337]
wO2024083953A1 Formula4
undisclosed
Undisclosed
Undisclosed
[337]
wO2024083953A1 Formula5
undisclosed
Undisclosed
Undisclosed
[337]
wO2024083953A1 Formula6
undisclosed
Undisclosed
Undisclosed
[337]
wO2024083953A1 Formula7
undisclosed
Undisclosed
Undisclosed
[337]
wO2024083953A1 Formula8
undisclosed
Undisclosed
Undisclosed
[337]
wO2024083953A1 Formula9
undisclosed
Undisclosed
Undisclosed
[337]
wO2024083953A1 Formula10
undisclosed
Undisclosed
Undisclosed
[337]
wO2024083953A1 Formula11
undisclosed
Undisclosed
Undisclosed
[337]
wO2024083953A1 Formula12
undisclosed
Undisclosed
Undisclosed
[337]
wO2024083953A1 Formula13
undisclosed
Undisclosed
Undisclosed
[337]
wO2024083953A1 Formula14
undisclosed
Undisclosed
Undisclosed
[337]
wO2024083953A1 Formula15
undisclosed
Undisclosed
Undisclosed
[337]
wO2024083953A1 Formula16
undisclosed
Undisclosed
Undisclosed
[337]
uS11833215B2 5A
Undisclosed
Undisclosed
Undisclosed
[338]
uS11833215B2 5B
Undisclosed
Undisclosed
Undisclosed
[338]
uS11833215B2 5C
Undisclosed
Undisclosed
Undisclosed
[338]
uS11833215B2 5D
Undisclosed
Undisclosed
Undisclosed
[338]
uS11833215B2 5E
Undisclosed
Undisclosed
Undisclosed
[338]
uS11833215B2 5F
Undisclosed
Undisclosed
Undisclosed
[338]
uS11833215B2 5G
Undisclosed
Undisclosed
Undisclosed
[338]
uS11833215B2 5H
Undisclosed
Undisclosed
Undisclosed
[338]
uS11833215B2 5I
Undisclosed
Undisclosed
Undisclosed
[338]
iGAC-2
IG-L-1 Payload
Undisclosed
IG-L-1 linker
[47]
iGAC-4
Smol006
Eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1)
MP-Ala-Ala-PAB
[47]
iGAC-6
IG-L-2 Payload
Undisclosed
MP-Ala-Ala-PAB
[47]
iGAC-8
Smol006
Eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1)
MP-Ala-Ala-PAB
[47]
iGAC-10
IG-L-1 Payload
Undisclosed
IG-L-1 linker
[47]
iGAC-12
IG-L-3 Payload
Undisclosed
IG-L-3 linker
[47]
iGAC-14
IG-L-7 Payload
Undisclosed
MP-Ala-Ala-PAB
[47]
iGAC-16
IG-L-4 Payload
Undisclosed
MP-Ala-Ala-PAB
[47]
iGAC-18
IG-L-5 Payload
Undisclosed
MP-Ala-Ala-PAB
[47]
iGAC-20
IG-L-9 Payload
Undisclosed
MP-Ala-Ala-PAB
[47]
iGAC-22
IG-L-10 Payload
Undisclosed
MP-Ala-Ala-PAB
[47]
iGAC-24
IG-L-11 Payload
Undisclosed
MP-Ala-Ala-PAB
[47]
iGAC-30
IG-L-12 Payload
Undisclosed
MP-Ala-Ala-PAB
[47]
jP7560255B2 ControlADC1
Undisclosed
Undisclosed
Undisclosed
[339]
jP7560255B2 ControlADC2
Undisclosed
Undisclosed
Undisclosed
[339]
jP7560255B2 ControlADC3
Undisclosed
Undisclosed
Undisclosed
[339]
jP7560255B2 ControlADC4
Undisclosed
Undisclosed
Undisclosed
[339]
jP7560255B2 ControlADC5
Undisclosed
Undisclosed
Undisclosed
[339]
jP7560255B2 ControlADC59 8
Undisclosed
Undisclosed
Undisclosed
[339]
jP7560255B2 ControlADC7
Undisclosed
Undisclosed
Undisclosed
[339]
jP7560255B2 ControlADC8
Undisclosed
Undisclosed
Undisclosed
[339]
jP7560255B2 ControlADC9
Undisclosed
Undisclosed
Undisclosed
[339]
jP7560255B2 ControlADC10
Undisclosed
Undisclosed
Undisclosed
[339]
jP7560255B2 ControlADC11
Undisclosed
Undisclosed
Undisclosed
[339]
jP7560255B2 ControlADC12
Undisclosed
Undisclosed
Undisclosed
[339]
jP7560255B2 ControlADC13
Undisclosed
Undisclosed
Undisclosed
[339]
jP7560255B2 ControlADC14
Undisclosed
Undisclosed
Undisclosed
[339]
jP7560255B2 ControlADC15
Undisclosed
Undisclosed
Undisclosed
[339]
jP7560255B2 ControlADC16
Undisclosed
Undisclosed
Undisclosed
[339]
jP7560255B2 ControlADC17
Undisclosed
Undisclosed
Undisclosed
[339]
jP7560255B2 ControlADC18
Undisclosed
Undisclosed
Undisclosed
[339]
jP7560255B2 ControlADC19
Undisclosed
Undisclosed
Undisclosed
[339]
jP7560255B2 ControlADC20
Undisclosed
Undisclosed
Undisclosed
[339]
jP7560255B2 ControlADC21
Undisclosed
Undisclosed
Undisclosed
[339]
jP7560255B2 ControlADC22
Undisclosed
Undisclosed
Undisclosed
[339]
jP7560255B2 ControlADC23
Undisclosed
Undisclosed
Undisclosed
[339]
jP7560255B2 ControlADC24
Undisclosed
Undisclosed
Undisclosed
[339]
jP7560255B2 ControlADC25
Undisclosed
Undisclosed
Undisclosed
[339]
jP7560255B2 ControlADC26
Undisclosed
Undisclosed
Undisclosed
[339]
jP7560255B2 ControlADC27
Undisclosed
Undisclosed
Undisclosed
[339]
jP7560255B2 ControlADC28
Undisclosed
Undisclosed
Undisclosed
[339]
jP7560255B2 ControlADC29
Undisclosed
Undisclosed
Undisclosed
[339]
jP7560255B2 ControlADC30
Undisclosed
Undisclosed
Undisclosed
[339]
jP7560255B2 ControlADC31
Undisclosed
Undisclosed
Undisclosed
[339]
jP7560255B2 ControlADC32
Undisclosed
Undisclosed
Undisclosed
[339]
jP7560255B2 ControlADC33
Undisclosed
Undisclosed
Undisclosed
[339]
jP7560255B2 ControlADC34
Undisclosed
Undisclosed
Undisclosed
[339]
jP7560255B2 ControlADC35
Undisclosed
Undisclosed
Undisclosed
[339]
jP7560255B2 ControlADC36
Undisclosed
Undisclosed
Undisclosed
[339]
jP7560255B2 ControlADC37
Undisclosed
Undisclosed
Undisclosed
[339]
jP7560255B2 ControlADC38
Undisclosed
Undisclosed
Undisclosed
[339]
jP7560255B2 ControlADC39
Undisclosed
Undisclosed
Undisclosed
[339]
jP7560255B2 ControlADC40
Undisclosed
Undisclosed
Undisclosed
[339]
jP7560255B2 ControlADC41
Undisclosed
Undisclosed
Undisclosed
[339]
jP7560255B2 ControlADC42
Undisclosed
Undisclosed
Undisclosed
[339]
jP7560255B2 ControlADC43
Undisclosed
Undisclosed
Undisclosed
[339]
jP7560255B2 ControlADC44
Undisclosed
Undisclosed
Undisclosed
[339]
jP7560255B2 ControlADC60
Undisclosed
Undisclosed
Undisclosed
[339]
jP7560255B2 ControlADC61
Undisclosed
Undisclosed
Undisclosed
[339]
tW202506738A C-009
TW202506738A-C-009-PAYLOAD
DNA topoisomerase I (TOP1)
TW202506738A-C-009-LINKER
[340]
tW202506738A C-020
TW202506738A-C-009-PAYLOAD
DNA topoisomerase I (TOP1)
TW202506738A-C-020-LINKER
[340]
tW202506738A C-025
TW202506738A-C-025-PAYLOAD
Undisclosed
TW202506738A-C-025-LINKER
[340]
tW202506738A C-027
TW202506738A-C-027-PAYLOAD
Undisclosed
TW202506738A-C-027-LINKER
[340]
tW202506738A C-031
Undisclosed
Undisclosed
Undisclosed
[340]
tW202506738A C-037
TW202506738A-C-037-PAYLOAD
Undisclosed
TW202506738A-C-009-LINKER
[340]
tW202506738A C-038
TW202506738A-C-037-PAYLOAD
Undisclosed
TW202506738A-C-025-LINKER
[340]
tW202506738A C-039
TW202506738A-C-037-PAYLOAD
Undisclosed
TW202506738A-C-039-LINKER
[340]
tW202506738A C-043
TW202506738A-C-037-PAYLOAD
Undisclosed
TW202506738A-C-043-LINKER
[340]
tW202506738A C-046
TW202506738A-C-046-PAYLOAD
Undisclosed
TW202506738A-C-046-LINKER
[340]
tW202506738A C-052
TW202506738A-C-052-PAYLOAD
Undisclosed
TW202506738A-C-046-LINKER
[340]
tW202506738A C-056
TW202506738A-C-056-PAYLOAD
Undisclosed
TW202506738A-C-056-LINKER
[340]
tW202506738A C-059
TW202506738A-C-059-PAYLOAD
Undisclosed
TW202506738A-C-059-LINKER
[340]
tW202506738A C-063
TW202506738A-C-063-PAYLOAD
Undisclosed
TW202506738A-C-063-LINKER
[340]
tW202506738A C-066
TW202506738A-C-066-PAYLOAD
Undisclosed
TW202506738A-C-066-LINKER
[340]
tW202506738A C-071
TW202506738A-C-071-PAYLOAD
Undisclosed
TW202506738A-C-071-LINKER
[340]
tW202506738A C-079
TW202506738A-C-079-PAYLOAD
Undisclosed
TW202506738A-C-079-LINKER
[340]
tW202506738A C-084
TW202506738A-C-084-PAYLOAD
Undisclosed
TW202506738A-C-084-LINKER
[340]
tW202506738A C-087
TW202506738A-C-087-PAYLOAD
Undisclosed
TW202506738A-C-087-LINKER
[340]
tW202506738A C-093
TW202506738A-C-093-PAYLOAD
Undisclosed
TW202506738A-C-093-LINKER
[340]
tW202506738A C-096
Topo1 inhibitor E
DNA topoisomerase I (TOP1)
TW202506738A-C-096-LINKER
[340]
tW202506738A C-102
TW202506738A-C-102-PAYLOAD
Undisclosed
TW202506738A-C-102-LINKER
[340]
tW202506738A C-109
TW202506738A-C-102-PAYLOAD
Undisclosed
TW202506738A-C-109-LINKER
[340]
tW202506738A C-111
Topo1 inhibitor E
DNA topoisomerase I (TOP1)
TW202506738A-C-111-LINKER
[340]
tW202506738A C-118
TW202506738A-C-118-PAYLOAD
Undisclosed
TW202506738A-C-118-LINKER
[340]
tW202506738A C-123
TW202506738A-C-123-PAYLOAD
Undisclosed
TW202506738A-C-123-LINKER
[340]
tW202506738A C-133
Topo1 inhibitor E
DNA topoisomerase I (TOP1)
TW202506738A-C-133-LINKER
[340]
tW202506738A C-155
Topo1 inhibitor E
DNA topoisomerase I (TOP1)
TW202506738A-C-155-LINKER
[340]
tW202506738A C-168
Topo1 inhibitor E
DNA topoisomerase I (TOP1)
TW202506738A-C-168-LINKER
[340]
tW202506738A C-172
Topo1 inhibitor E
DNA topoisomerase I (TOP1)
TW202506738A-C-172-LINKER
[340]
tW202506738A C-182
Topo1 inhibitor G
DNA topoisomerase I (TOP1)
TW202506738A-C-182-LINKER
[340]
tW202506738A C-186
Topo1 inhibitor G
DNA topoisomerase I (TOP1)
TW202506738A-C-186-LINKER
[340]
tW202506738A C-208
Exatecan
Undisclosed
TW202506738A-C-208-LINKER
[340]
tW202506738A C-214
TW202506738A-C-214-PAYLOAD
Undisclosed
TW202506738A-C-214-LINKER
[340]
tW202506738A C-215
TW202506738A-C-215-PAYLOAD
Undisclosed
TW202506738A-C-214-LINKER
[340]
tW202506738A C-216
TW202506738A-C-216-PAYLOAD
Undisclosed
TW202506738A-C-214-LINKER
[340]
tW202506738A C-217
TW202506738A-C-216-PAYLOAD
Undisclosed
TW202506738A-C-217-LINKER
[340]
tW202506738A C-218
TW202506738A-C-218-PAYLOAD
Undisclosed
TW202506738A-C-217-LINKER
[340]
tW202506738A C-226
TW202506738A-C-226-PAYLOAD
Undisclosed
TW202506738A-C-226-LINKER
[340]
tW202506738A C-227
TW202506738A-C-227-PAYLOAD
Undisclosed
TW202506738A-C-226-LINKER
[340]
tW202506738A C-231
TW202506738A-C-231-PAYLOAD
Undisclosed
TW202506738A-C-226-LINKER
[340]
tW202506738A C-237
Undisclosed
Undisclosed
Undisclosed
[340]
tW202506738A C-325
TW202506738A-C-325-PAYLOAD
Undisclosed
TW202506738A-C-325-LINKER
[340]
tW202506738A C-326
TW202506738A-C-326-PAYLOAD
Undisclosed
TW202506738A-C-325-LINKER
[340]
tW202506738A C-327
TW202506738A-C-327-PAYLOAD
Undisclosed
TW202506738A-C-327-LINKER
[340]
tW202506738A C-328
TW202506738A-C-327-PAYLOAD
Undisclosed
TW202506738A-C-325-LINKER
[340]
tW202506738A C-329
TW202506738A-C-329-PAYLOAD
Undisclosed
TW202506738A-C-327-LINKER
[340]
tW202506738A C-330
TW202506738A-C-330-PAYLOAD
Undisclosed
TW202506738A-C-327-LINKER
[340]
tW202506738A C-331
TW202506738A-C-331-PAYLOAD
Undisclosed
TW202506738A-C-327-LINKER
[340]
tW202506738A C-332
TW202506738A-C-332-PAYLOAD
Microtubule (MT)
TW202506738A-C-327-LINKER
[340]
tW202506738A C-333
TW202506738A-C-332-PAYLOAD
Microtubule (MT)
TW202506738A-C-333-LINKER
[340]
tW202506738A C-334
TW202506738A-C-332-PAYLOAD
Microtubule (MT)
TW202506738A-C-333-LINKER
[340]
tW202506738A C-335
TW202506738A-C-332-PAYLOAD
Microtubule (MT)
TW202506738A-C-335-LINKER
[340]
tW202506738A C-353
TW202506738A-C-353-PAYLOAD
Undisclosed
TW202506738A-C-353-LINKER
[340]
tW202506738A C-363
TW202506738A-C-363-PAYLOAD
Undisclosed
TW202506738A-C-353-LINKER
[340]
tW202506738A C-397
TW202506738A-C-397-PAYLOAD
Undisclosed
TW202506738A-C-397-LINKER
[340]
tW202506738A C-400
TW202506738A-C-400-PAYLOAD
Undisclosed
TW202506738A-C-400-LINKER
[340]
cN113318238B ADC-1
Undisclosed
Undisclosed
Undisclosed
[341]
cN113318238B ADC-2
Undisclosed
Undisclosed
Undisclosed
[341]
cN113318238B ADC-3
Undisclosed
Undisclosed
Undisclosed
[341]
cN113318238B ADC-4
Undisclosed
Undisclosed
Undisclosed
[341]
cN113318238B ADC-5
Undisclosed
Undisclosed
Undisclosed
[341]
cN113318238B ADC-6
Undisclosed
Undisclosed
Undisclosed
[341]
cN113318238B ADC-7
Undisclosed
Undisclosed
Undisclosed
[341]
cN113318238B ADC-8
Undisclosed
Undisclosed
Undisclosed
[341]
cN113318238B ADC-9
Undisclosed
Undisclosed
Undisclosed
[341]
cN113318238B ADC-10
Undisclosed
Undisclosed
Undisclosed
[341]
cN119630431A ADC-82
CN119630431A-ADC-82-PAYLOAD
Undisclosed
CN119630431A-ADC-82-LINKER
[5]
cN119630431A ADC-83
CN119630431A-ADC-82-PAYLOAD
Undisclosed
CN119630431A-ADC-82-LINKER
[5]
cN119630431A ADC-84
CN119630431A-ADC-82-PAYLOAD
Undisclosed
CN119630431A-ADC-83-LINKER
[5]
cN119630431A ADC-85
CN119630431A-ADC-84-PAYLOAD
Undisclosed
CN119630431A-ADC-67-LINKER
[5]
cN119630431A ADC-86
CN119630431A-ADC-82-PAYLOAD
Undisclosed
CN119630431A-ADC-82-LINKER
[5]
cN119630431A ADC-87
CN119630431A-ADC-82-PAYLOAD
Undisclosed
CN119630431A-ADC-82-LINKER
[5]
cN119630431A ADC-88
CN119630431A-ADC-82-PAYLOAD
Undisclosed
CN119630431A-ADC-83-LINKER
[5]
cN119630431A ADC-89
CN119630431A-ADC-84-PAYLOAD
Undisclosed
CN119630431A-ADC-67-LINKER
[5]
cN119630431A ADC-93
CN119630431A-ADC-82-PAYLOAD
Undisclosed
CN119630431A-ADC-82-LINKER
[5]
cN119630431A ADC-95
CN119630431A-ADC-82-PAYLOAD
Undisclosed
CN119630431A-ADC-82-LINKER
[5]
cN119630431A ADC-96
CN119630431A-ADC-82-PAYLOAD
Undisclosed
CN119630431A-ADC-82-LINKER
[5]
cN119630431A ADC-97
CN119630431A-ADC-82-PAYLOAD
Undisclosed
CN119630431A-ADC-82-LINKER
[5]
cN119630431A ADC-98
CN119630431A-ADC-82-PAYLOAD
Undisclosed
CN119630431A-ADC-82-LINKER
[5]
mK-6204
Undisclosed
Undisclosed
Undisclosed
sLV-154
Undisclosed
Undisclosed
Undisclosed
aBBV-324
Undisclosed
Undisclosed
Undisclosed
mHB046C
TOP1 inhibitor
DNA topoisomerase 1 (TOP1)
A cleavable linker
sLV-324
Undisclosed
Undisclosed
Undisclosed
pHN-012
Undisclosed
Undisclosed
Undisclosed
mBRC-201
Undisclosed
Undisclosed
Undisclosed
wEF-001
Monomethyl auristatin E
Microtubule (MT)
Undisclosed
fS001
TOP1 inhibitor
DNA topoisomerase 1 (TOP1)
A cleavable linker
bL-M24D1
WA-00
Microtubule (MT)
Undisclosed
oNA-255
Undisclosed
Undisclosed
Undisclosed
aBBV-901
Undisclosed
Undisclosed
Undisclosed
aDCE-B05
Undisclosed
Undisclosed
Undisclosed
aK0406
Undisclosed
Undisclosed
Undisclosed
tORL-5-700
Undisclosed
Undisclosed
Undisclosed
mG2002A
Undisclosed
Undisclosed
Undisclosed
mG2001
Undisclosed
Undisclosed
Undisclosed
mG1901
Undisclosed
Undisclosed
Undisclosed
tarcocimab tedromer
Undisclosed
Undisclosed
Undisclosed
kSI-501
Undisclosed
Undisclosed
Undisclosed
aDCX-020
TOP1 inhibitor
DNA topoisomerase 1 (TOP1)
A cleavable linker
Undisclosed
ADC Info ADC Name Payload Target Linker Ref
CPO-204
Undisclosed
Undisclosed
Undisclosed
MG-1901
Undisclosed
Undisclosed
Undisclosed
MG-2001
Undisclosed
Undisclosed
Undisclosed
MG-2002A
Undisclosed
Undisclosed
Undisclosed
131I-ImmuRAIT-HCG
Undisclosed
Undisclosed
Undisclosed
[54]
NBT-588
Undisclosed
Undisclosed
Undisclosed
[55]
NBT-588
Undisclosed
Undisclosed
Undisclosed
[55]
RC-168
Undisclosed
Undisclosed
Undisclosed
[56]
RC-178
Undisclosed
Undisclosed
Undisclosed
[56]
RC-188
Undisclosed
Undisclosed
Undisclosed
[56]
XNW-28012
Undisclosed
Undisclosed
Undisclosed
[57]
Bi-specific antibody drug conjugate
Undisclosed
Undisclosed
Undisclosed
[58]
ZV03-ADC
Undisclosed
Undisclosed
Undisclosed
[59]
AR081
Undisclosed
Undisclosed
Undisclosed
[60]
BC5084
Undisclosed
Undisclosed
Undisclosed
[61]
WTX-116
Undisclosed
Undisclosed
Undisclosed
[62]
WTX-231
Undisclosed
Undisclosed
Undisclosed
[62]
WTX-222
Undisclosed
Undisclosed
Undisclosed
[62]
VIS-705
Undisclosed
Undisclosed
Undisclosed
[63]
Second ADC (Virtuoso Therapeutics)
Undisclosed
Undisclosed
Undisclosed
[64]
LEAD ADC (Virtuoso Therapeutics)
Undisclosed
Undisclosed
Undisclosed
[65]
Additional antibody drug conjugate (Virtuoso Therapeutics)
Undisclosed
Undisclosed
Undisclosed
[66]
VLS-301
Undisclosed
Undisclosed
Undisclosed
[67]
VLS-201
Undisclosed
Undisclosed
Undisclosed
[68]
Vas-202
Undisclosed
Undisclosed
Undisclosed
[69]
Vas-201
Undisclosed
Undisclosed
Undisclosed
[70]
Anticancer antibody-drug conjugate (Vaccinex/Catalent Pharma Solutions)
Undisclosed
Undisclosed
Undisclosed
[71]
TUB-060
Undisclosed
Undisclosed
Undisclosed
[72]
TUB-050
Undisclosed
Undisclosed
Undisclosed
[72]
TAE-020
Undisclosed
Undisclosed
Undisclosed
[73]
TT-01
Undisclosed
Undisclosed
Undisclosed
[74]
TGM-005
Undisclosed
Undisclosed
Undisclosed
[75]
TGM-004
Undisclosed
Undisclosed
Undisclosed
[76]
TGM-003
Undisclosed
Undisclosed
Undisclosed
[77]
TGM-002
Undisclosed
Undisclosed
Undisclosed
[78]
Antibody boron conjugate radiopharmaceuticals (TAE Life Sciences)
Undisclosed
Undisclosed
Undisclosed
[79]
SIM-005A
Undisclosed
Undisclosed
Undisclosed
[80]
SIM-002A
Undisclosed
Undisclosed
Undisclosed
[81]
SIB-004A
Undisclosed
Undisclosed
Undisclosed
[82]
BL-B029A1
Undisclosed
Undisclosed
Undisclosed
[83]
BL-M002A2
Undisclosed
Undisclosed
Undisclosed
[84]
Antibody-drug conjugate 4 (Synthon)
Undisclosed
Undisclosed
Undisclosed
[85]
Antibody-drug conjugate 3 (Synthon)
Undisclosed
Undisclosed
Undisclosed
[86]
SAB-Y17
Undisclosed
Undisclosed
Undisclosed
[87]
SAB-Y1
Undisclosed
Undisclosed
Undisclosed
[87]
SDV-1001
Undisclosed
Undisclosed
Undisclosed
[88]
Antibody-drug conjugate (SynAffix)
Undisclosed
Undisclosed
Undisclosed
[89]
ADC project 7 (Suzhou Medilink Therapeutics Ltd.)
Undisclosed
Undisclosed
Undisclosed
[90]
ADC project 6 (Suzhou Medilink Therapeutics Ltd.)
Undisclosed
Undisclosed
Undisclosed
[90]
ADC project 5 (Suzhou Medilink Therapeutics Ltd.)
Undisclosed
Undisclosed
Undisclosed
[90]
ADC project 4 (Suzhou Medilink Therapeutics Ltd.)
Undisclosed
Undisclosed
Undisclosed
[90]
BsAb-ADC (Medilink Therapeutics)
Undisclosed
Undisclosed
Undisclosed
[91]
SOT106
Undisclosed
Undisclosed
Undisclosed
[92]
SMD-5033
Undisclosed
Undisclosed
Undisclosed
[93]
SMD-3117
Undisclosed
Undisclosed
Undisclosed
[94]
HY-0001
Undisclosed
Undisclosed
Undisclosed
[95]
BL-M005
Undisclosed
Undisclosed
Undisclosed
[96]
BL-M22D1
Undisclosed
Undisclosed
Undisclosed
[97]
P-BsAb-ADC
Undisclosed
Undisclosed
Undisclosed
[98]
JY210
Undisclosed
Undisclosed
Undisclosed
[99]
JY208
Undisclosed
Undisclosed
Undisclosed
[99]
SY-1558
Undisclosed
Undisclosed
Undisclosed
[100]
MRG-006
Undisclosed
Undisclosed
Undisclosed
[101]
MRX-23
Undisclosed
Undisclosed
Undisclosed
[102]
MG2106E
Undisclosed
Undisclosed
Undisclosed
[103]
MG2018
Undisclosed
Undisclosed
Undisclosed
[103]
MG2011C
Undisclosed
Undisclosed
Undisclosed
[103]
MG2002B
Undisclosed
Undisclosed
Undisclosed
[103]
Antibody-drug conjugate (Sanofi/Seagen)
Undisclosed
Undisclosed
Undisclosed
[104]
SGN-25
Undisclosed
Undisclosed
Undisclosed
[105]
APEC-3
Undisclosed
Undisclosed
Undisclosed
[106]
APEC-2
Undisclosed
Undisclosed
Undisclosed
[107]
RAD-501
Undisclosed
Undisclosed
Undisclosed
[108]
PLBC-003
Undisclosed
Undisclosed
Undisclosed
[109]
PLBC-002
Undisclosed
Undisclosed
Undisclosed
[109]
PLBC-001
Undisclosed
Undisclosed
Undisclosed
[109]
PLBA-005
Undisclosed
Undisclosed
Undisclosed
[109]
PLBA-004
Undisclosed
Undisclosed
Undisclosed
[109]
PLBA-003
Undisclosed
Undisclosed
Undisclosed
[109]
PLBA-002
Undisclosed
Undisclosed
Undisclosed
[109]
PLBA-001
Undisclosed
Undisclosed
Undisclosed
[109]
PSM-101
Undisclosed
Undisclosed
Undisclosed
[110]
DN-028
Undisclosed
Undisclosed
Undisclosed
[111]
DN-027
Undisclosed
Undisclosed
Undisclosed
[112]
PHN-020
Undisclosed
Undisclosed
Undisclosed
[113]
Antibody-drug conjugate containing OXS-2175 (Oxis Biotech/MultiCell ImmunoTherapeutics)
Undisclosed
Undisclosed
Undisclosed
[114]
OX-004
Undisclosed
Undisclosed
Undisclosed
[115]
Antibody-drug conjugate (Oxford BioTherapeutics/Boehringer Ingelheim)
Undisclosed
Undisclosed
Undisclosed
[116]
OBT542
Undisclosed
Undisclosed
Undisclosed
[117]
OBT207
Undisclosed
Undisclosed
Undisclosed
[117]
OBT029
Undisclosed
Undisclosed
Undisclosed
[117]
Next generation antibody-drug conjugate (Oxford BioTherapeutics)
Undisclosed
Undisclosed
Undisclosed
[118]
NBT-598
Undisclosed
Undisclosed
Undisclosed
[119]
NBT-578
Undisclosed
Undisclosed
Undisclosed
[120]
NBT-568
Undisclosed
Undisclosed
Undisclosed
[121]
NBT-528
Undisclosed
Undisclosed
Undisclosed
[122]
NW-12-005
Undisclosed
Undisclosed
Undisclosed
[123]
NTX-1107
Undisclosed
Undisclosed
Undisclosed
[124]
SO-N107
Undisclosed
Undisclosed
Undisclosed
[125]
NBE-003
Undisclosed
Undisclosed
Undisclosed
[126]
NBE-001
Undisclosed
Undisclosed
Undisclosed
[127]
MBC-301
Undisclosed
Undisclosed
Undisclosed
[128]
G-100 (Magenta Therapeutics)
Undisclosed
Undisclosed
Undisclosed
[129]
MBK-101
Undisclosed
Undisclosed
Undisclosed
[130]
LCB-69
Undisclosed
Undisclosed
Undisclosed
[131]
LCB-91
Undisclosed
Undisclosed
Undisclosed
[131]
LCB-09A
Undisclosed
Undisclosed
Undisclosed
[131]
LCB-42A
Undisclosed
Undisclosed
Undisclosed
[131]
LCB-20A
Undisclosed
Undisclosed
Undisclosed
[131]
LCB-19A
Undisclosed
Undisclosed
Undisclosed
[131]
LCB-18A
Undisclosed
Undisclosed
Undisclosed
[131]
LCB14-15nm
Undisclosed
Undisclosed
Undisclosed
[132]
LCB-12A
Undisclosed
Undisclosed
Undisclosed
[131]
LCB-06A
Undisclosed
Undisclosed
Undisclosed
[131]
LCB-04A
Undisclosed
Undisclosed
Undisclosed
[131]
LCB-02A
Undisclosed
Undisclosed
Undisclosed
[131]
LCB-88
Undisclosed
Undisclosed
Undisclosed
[133]
LCB-85
Undisclosed
Undisclosed
Undisclosed
[131]
LP-A18
Undisclosed
Undisclosed
Undisclosed
[134]
LM-007
Undisclosed
Undisclosed
Undisclosed
[135]
LM-006
Undisclosed
Undisclosed
Undisclosed
[135]
LM-005
Undisclosed
Undisclosed
Undisclosed
[135]
LM-004
Undisclosed
Undisclosed
Undisclosed
[135]
LM-001
Undisclosed
Undisclosed
Undisclosed
[135]
LM-317
Undisclosed
Undisclosed
Undisclosed
[136]
LM-008
Undisclosed
Undisclosed
Undisclosed
[135]
KGX201
Undisclosed
Undisclosed
Undisclosed
[137]
IOG-101
Undisclosed
Undisclosed
Undisclosed
[138]
DBAF-301
Undisclosed
Undisclosed
Undisclosed
[139]
IN30718
Undisclosed
Undisclosed
Undisclosed
[140]
IMB-213I
Undisclosed
Undisclosed
Undisclosed
[141]
IMB-212
Undisclosed
Undisclosed
Undisclosed
[141]
IKS-02
Undisclosed
Undisclosed
Undisclosed
[142]
IKS-04
Undisclosed
Undisclosed
Undisclosed
[142]
Glaucoma therapy
Undisclosed
Undisclosed
Undisclosed
[143]
HDP-104
Undisclosed
Undisclosed
Undisclosed
[144]
DXC-020
Undisclosed
Undisclosed
Undisclosed
[145]
DXC-019
Undisclosed
Undisclosed
Undisclosed
[145]
DXC-018
Undisclosed
Undisclosed
Undisclosed
[145]
DXC-017
Undisclosed
Undisclosed
Undisclosed
[145]
DXC-016
Undisclosed
Undisclosed
Undisclosed
[145]
DXC-015
Undisclosed
Undisclosed
Undisclosed
[145]
DXC-013
Undisclosed
Undisclosed
Undisclosed
[145]
DXC-012
Undisclosed
Undisclosed
Undisclosed
[145]
DXC-011
Undisclosed
Undisclosed
Undisclosed
[145]
DXC-010
Undisclosed
Undisclosed
Undisclosed
[145]
Monoclonal Antibody-Drug Conjugate (Kind Pharmaceuticals)
Undisclosed
Undisclosed
Undisclosed
[146]
GBM-12401
Undisclosed
Undisclosed
Undisclosed
[147]
GMA-305
Undisclosed
Undisclosed
Undisclosed
[148]
GMA-205
Undisclosed
Undisclosed
Undisclosed
[149]
SeeloMab-GEX
Undisclosed
Undisclosed
Undisclosed
[150]
P-1000
Undisclosed
Undisclosed
Undisclosed
[151]
GL-231
Undisclosed
Undisclosed
Undisclosed
[152]
GF-2014
Undisclosed
Undisclosed
Undisclosed
[153]
GR1018
Undisclosed
Undisclosed
Undisclosed
[154]
GR-1016
Undisclosed
Undisclosed
Undisclosed
[154]
GR-1015
Undisclosed
Undisclosed
Undisclosed
[154]
GR-1014
Undisclosed
Undisclosed
Undisclosed
[154]
GQ-1009
Undisclosed
Undisclosed
Undisclosed
[154]
M-131
Undisclosed
Undisclosed
Undisclosed
[155]
EVOLVE-104 ADC
Undisclosed
Undisclosed
Undisclosed
[156]
EP-400
Undisclosed
Undisclosed
Undisclosed
[157]
PCG-N003
Undisclosed
Undisclosed
Undisclosed
[158]
PCG-C006
Undisclosed
Undisclosed
Undisclosed
[158]
PCG-C004
Undisclosed
Undisclosed
Undisclosed
[158]
PCG-C002
Undisclosed
Undisclosed
Undisclosed
[158]
DOM-1314
Undisclosed
Undisclosed
Undisclosed
[159]
AccuADC-001
Undisclosed
Undisclosed
Undisclosed
[160]
CM-09
Undisclosed
Undisclosed
Undisclosed
[161]
CS-5002
Undisclosed
Undisclosed
Undisclosed
[162]
CBP-1609
Undisclosed
Undisclosed
Undisclosed
[163]
Antiviral Fc-conjugate (Cidara Therapeutics)
Undisclosed
Undisclosed
Undisclosed
[164]
CRB-2107
Undisclosed
Undisclosed
Undisclosed
[165]
Monoclonal Antibody-Drug conjugate (Celltrion Chemical Research Institute/Immunogen/Celltrion)
Undisclosed
Undisclosed
Undisclosed
[166]
CT-P26
Undisclosed
Undisclosed
Undisclosed
[167]
CAT-03-106
Undisclosed
Undisclosed
Undisclosed
[168]
BMT-125961
Undisclosed
Undisclosed
Undisclosed
[169]
BRKB-28
Undisclosed
Undisclosed
Undisclosed
[170]
BIO104
Undisclosed
Undisclosed
Undisclosed
[171]
BIO103
Undisclosed
Undisclosed
Undisclosed
[171]
LD016
Undisclosed
Undisclosed
Undisclosed
[172]
BSC-4201
Undisclosed
Undisclosed
Undisclosed
[173]
BSC-4101
Undisclosed
Undisclosed
Undisclosed
[174]
BSI-023
Undisclosed
Undisclosed
Undisclosed
[175]
BIOO-4
Undisclosed
Undisclosed
Undisclosed
[176]
BIOO-3
Undisclosed
Undisclosed
Undisclosed
[177]
BIOO-2
Undisclosed
Undisclosed
Undisclosed
[178]
BIOO-1
Undisclosed
Undisclosed
Undisclosed
[179]
BIO-201
Undisclosed
Undisclosed
Undisclosed
[180]
BIO-108
Undisclosed
Undisclosed
Undisclosed
[180]
BIO-107
Undisclosed
Undisclosed
Undisclosed
[180]
BIO-110
Undisclosed
Undisclosed
Undisclosed
[180]
BIO-109
Undisclosed
Undisclosed
Undisclosed
[180]
Advanced antibody drug conjugate (Belrose Pharma)
Undisclosed
Undisclosed
Undisclosed
[181]
NX-08
Undisclosed
Undisclosed
Undisclosed
[182]
JY-023
Undisclosed
Undisclosed
Undisclosed
[183]
AT-01
Undisclosed
Undisclosed
Undisclosed
[184]
AT-00
Undisclosed
Undisclosed
Undisclosed
[185]
AT-04
Undisclosed
Undisclosed
Undisclosed
[184]
AVP20
Undisclosed
Undisclosed
Undisclosed
[186]
Antibody drug conjugate containing duocarmycin analogue
Undisclosed
Undisclosed
Undisclosed
[187]
Antibody drug conjugate (Halozyme)
Undisclosed
Undisclosed
Undisclosed
[188]
APB-CS
Undisclosed
Undisclosed
Undisclosed
[189]
Monoclonal Antibody-Drug Conjugate (Antengene)
Undisclosed
Undisclosed
Undisclosed
[190]
ANG-101
Undisclosed
Undisclosed
Undisclosed
[191]
Anti-cancer therapeutic (Amgen)
Undisclosed
Undisclosed
Undisclosed
[192]
AK 30 NGF
Undisclosed
Undisclosed
Undisclosed
[193]
AMB-015
Undisclosed
Undisclosed
Undisclosed
[194]
ADRX-863
Undisclosed
Undisclosed
Undisclosed
[195]
AbGn-108
Undisclosed
Undisclosed
Undisclosed
[196]
BIO-112
Undisclosed
Undisclosed
Undisclosed
[180]
STING based antibody-drug conjugate (Exelixis)
STING agonist
Stimulator of interferon genes protein (STING1)
Undisclosed
[197]
BL-M005A2
Dual-warhead
Undisclosed
Undisclosed
[198]
SMP-190
DX-8951 derivative (DXd)
DNA topoisomerase 1 (TOP1)
Unique hydrophilic Linker
[199]
CBX-13
Mertansine DM4
Microtubule (MT)
Undisclosed
[200]
PTM-001-ADC
Mertansine DM1
Microtubule (MT)
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
[201]
APH-0912
Docetaxel
Microtubule (MT)
Hydrophilic linker containing sugar molecules
[202]
Dual-payload ADC (Mersana Therapeutics)
AF-HPA+DNA monoalkylator I-BiP
Ribosome (RB); Human Deoxyribonucleic acid (hDNA)
Undisclosed
[203]
TAK-ATACs
Alpha-amanitin
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
Undisclosed
[204]
Antibody targeted amanitin conjugate
Alpha-amanitin
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
Undisclosed
[205]
Alpha-amanitin antibody-drug conjugate (Agensys)
Alpha-amanitin
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
Undisclosed
[206]
Eribulin ADC (Jiangsu hengrui)
Eribulin
Microtubule (MT)
Undisclosed
[207]
CBX-14
Multi-targetd DDR inhibitor
Epithelial discoidin domain-containing receptor 1 (DDR1)
Undisclosed
[200]
Masked ADC (Adagene/ADC Therapeutics)
PBD dimer
Human Deoxyribonucleic acid (hDNA)
Undisclosed
[208]
Spliceostatin-antibody-drug conjugate
Spliceostatin A
Splicing factor 3B subunit 1 (SF3B1)
Undisclosed
[209]
XMT-2175
STING agonist
Stimulator of interferon genes protein (STING1)
Undisclosed
[210]
XMT-2068
STING agonist
Stimulator of interferon genes protein (STING1)
Undisclosed
[210]
STING agonist ADC
STING agonist
Stimulator of interferon genes protein (STING1)
Undisclosed
[211]
EX108
Undisclosed
Undisclosed
Undisclosed
[212]
ADC2313
Undisclosed
Undisclosed
Undisclosed
[213]
ADC2154
Undisclosed
Undisclosed
Undisclosed
[214]
ADC2231
Undisclosed
Undisclosed
Undisclosed
[215]
ADC2335
Undisclosed
Undisclosed
Undisclosed
[216]
ADC2317
Undisclosed
Undisclosed
Undisclosed
[217]
BR-2202
Undisclosed
Undisclosed
Undisclosed
[218]
BR-2102
Undisclosed
Undisclosed
Undisclosed
[218]
BR-2003
Undisclosed
Undisclosed
Undisclosed
[218]
BB-1708
Undisclosed
Undisclosed
Undisclosed
[218]
BB-1706
Undisclosed
Undisclosed
Undisclosed
[218]
BB-1710
Undisclosed
Undisclosed
Undisclosed
[218]
MABS-01
Undisclosed
Undisclosed
Undisclosed
[219]
MABS-02
Undisclosed
Undisclosed
Undisclosed
[219]
PBX-002
Undisclosed
Undisclosed
Undisclosed
[220]
SY-1700
Undisclosed
Undisclosed
Undisclosed
[221]
SY-1274
Undisclosed
Undisclosed
Undisclosed
[221]
SY-0831
Undisclosed
Undisclosed
Undisclosed
[221]
SY-1330
Undisclosed
Undisclosed
Undisclosed
[221]
SY-0833
Undisclosed
Undisclosed
Undisclosed
[221]
SY-1211
Undisclosed
Undisclosed
Undisclosed
[221]
SY-0625
Undisclosed
Undisclosed
Undisclosed
[221]
BRKB-44
Undisclosed
Undisclosed
Undisclosed
[222]
AMB-101
Topoisomerase I inhibitor
DNA topoisomerase 1 (TOP1)
Undisclosed
[223]
AMB-102
Undisclosed
Undisclosed
Undisclosed
[224]
BP-A102
Undisclosed
Undisclosed
Undisclosed
[225]
BP-A103
Undisclosed
Undisclosed
Undisclosed
[225]
AU-011
IRDye 700DX
Undisclosed
Undisclosed
[226]
IMB-202
Undisclosed
Undisclosed
Undisclosed
[227]
3-NAntC
Undisclosed
Undisclosed
Undisclosed
[228]
BIO105
Undisclosed
Undisclosed
Undisclosed
[229]
CO-1003
Undisclosed
Undisclosed
Undisclosed
[230]
CO-1023
Undisclosed
Undisclosed
Undisclosed
[230]
BR107
Undisclosed
Undisclosed
Undisclosed
[231]
BR109
Undisclosed
Undisclosed
Undisclosed
[232]
BRY811
Undisclosed
Undisclosed
Undisclosed
[233]
OTV:CH2
Undisclosed
Undisclosed
Undisclosed
[234]
OTV:LF3
Undisclosed
Undisclosed
Undisclosed
[234]
IN30728
Undisclosed
Undisclosed
Undisclosed
[235]
NW-001
Undisclosed
Undisclosed
Undisclosed
[236]
FG-B310
Undisclosed
Undisclosed
Undisclosed
[237]
FG-M131
Undisclosed
Undisclosed
Undisclosed
[237]
ADC001 (Arbele)
Undisclosed
Undisclosed
Undisclosed
[238]
ADC002 (Arbele)
Undisclosed
Undisclosed
Undisclosed
[238]
ADC003 (Arbele)
Undisclosed
Undisclosed
Undisclosed
[238]
TST013
Undisclosed
Undisclosed
Undisclosed
[239]
CS5005
Undisclosed
Undisclosed
Undisclosed
[240]
CS5006
Undisclosed
Undisclosed
Undisclosed
[240]
Monovalent Azymatic Antibody Drug Conjugate (Zymeworks)
Undisclosed
Undisclosed
Undisclosed
[241]
Antibody-drug conjugate (University of Toronto/ImmunoBiochem)
Undisclosed
Undisclosed
Undisclosed
[242]
Antibody-drug conjugate (University of Toronto/Advanced Proteome Therapeutics)
Undisclosed
Undisclosed
Undisclosed
[243]
Multi-functional antibody drug conjugate combination therapeutics (Sutro Biopharma/Celgene)
Undisclosed
Undisclosed
Undisclosed
[244]
MRG-009
Undisclosed
Undisclosed
Undisclosed
[245]
MRG-008
Undisclosed
Undisclosed
Undisclosed
[246]
MRG-007
Undisclosed
Undisclosed
Undisclosed
[247]
MRG-005
Undisclosed
Undisclosed
Undisclosed
[248]
LCB14-2nm
Undisclosed
Undisclosed
Undisclosed
[249]
CYP-Ab
Undisclosed
Undisclosed
Undisclosed
[250]
Antibody drug conjugate (Sanofi)
Undisclosed
Undisclosed
Undisclosed
[251]
Antibody drug conjugate (Compugen)
Undisclosed
Undisclosed
Undisclosed
[252]
Antibody-drug conjugate therapy (Neoantigenics)
Undisclosed
Undisclosed
Undisclosed
[253]
Antibody drug conjugate (Meditope Biosciences)
Undisclosed
Undisclosed
Undisclosed
[254]
LIN-003
Undisclosed
Undisclosed
Undisclosed
[255]
KSI-201
Undisclosed
Undisclosed
Undisclosed
[256]
Antibody drug conjugate (Intrexon)
Undisclosed
Undisclosed
Undisclosed
[257]
CRC-02 targeting antibody-drug conjugate
Undisclosed
Undisclosed
Undisclosed
[258]
Antibody-drug conjugate (Daiichi Sankyo)
Undisclosed
Undisclosed
Undisclosed
[259]
Antibody drug conjugate (Asana BioSciences)
Undisclosed
Undisclosed
Undisclosed
[260]
BIOO-7
Undisclosed
Undisclosed
Undisclosed
[261]
BIOO-6
Undisclosed
Undisclosed
Undisclosed
[262]
BIOO-5
Undisclosed
Undisclosed
Undisclosed
[263]
Antibody-drug conjugate (Bristol-Myers Squibb)
Undisclosed
Undisclosed
Undisclosed
[264]
Marine-derived cytotoxic payloads antibody-drug conjugation
Undisclosed
Undisclosed
Undisclosed
[265]
Antibody drug conjugate (Five Prime cancer)
Undisclosed
Undisclosed
Undisclosed
[266]
CBX-12
Exatecan
DNA topoisomerase 1 (TOP1)
Undisclosed
[267]
DAN-222
Undisclosed
Undisclosed
Undisclosed
[268]
CHB-111
Undisclosed
Undisclosed
Undisclosed
[269]
RG-7986
Undisclosed
Undisclosed
Undisclosed
[270]
DS001
Undisclosed
Undisclosed
Undisclosed
[271]
mAb2-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[321]
mAb3-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[321]
mAb4-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[321]
mAb5-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[321]
mAb6-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[321]
mAb7-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[321]
mAb8-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[321]
mAb9-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[321]
mAb10-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[321]
mAb11-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[321]
mAb12-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[321]
mAb13-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[321]
mAb14-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[321]
mAb15-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[321]
mAb16-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[321]
mAb17-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[321]
mAb18-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[321]
mAb2-MMAF
Monomethyl auristatin F
Microtubule (MT)
Mc-Val-Cit-PABC
[321]
mAb3-MMAF
Monomethyl auristatin F
Microtubule (MT)
Mc-Val-Cit-PABC
[321]
mAb17-MMAF
Monomethyl auristatin F
Microtubule (MT)
Mc-Val-Cit-PABC
[321]
mAb2-DXd
DX-8951 derivative (DXd)
DNA topoisomerase 1 (TOP1)
Mc-Gly-Gly-Phe-Gly
[321]
mAb3-DXd
DX-8951 derivative (DXd)
DNA topoisomerase 1 (TOP1)
Mc-Gly-Gly-Phe-Gly
[321]
mAb17-DXd
DX-8951 derivative (DXd)
DNA topoisomerase 1 (TOP1)
Mc-Gly-Gly-Phe-Gly
[321]
mAb2-MMAF+MMAE 1
Undisclosed
Undisclosed
Undisclosed
[321]
mAb1-MMAF+GGFG-DXd
Undisclosed
Undisclosed
Undisclosed
[321]
mAb1-MMAF+CL2A-SN38
Undisclosed
Undisclosed
Undisclosed
[321]
mAb2-MMAE+MMAF
Undisclosed
Undisclosed
Undisclosed
[321]
mAb2-MMAE+GGFG-DXd
Undisclosed
Undisclosed
Undisclosed
[321]
mAb2-MMAE+CL2A-SN38
Undisclosed
Undisclosed
Undisclosed
[321]
mAb2-MMAF+MMAE 2
Undisclosed
Undisclosed
Undisclosed
[321]
mAb2-MMAF+CL2A-SN38
Undisclosed
Undisclosed
Undisclosed
[321]
mAb3-MMAE+DXd
Undisclosed
Undisclosed
Undisclosed
[321]
isumab04-C5
compound 5
DNA topoisomerase I (TOP1)
Undisclosed
[322]
isumab04-C6
WO2025015586A1, ADC24, Payload
Toll-like receptor 7 (TLR7); Toll-like receptor 8 (TLR8)
Undisclosed
[322]
diS-Compound -145
FD6
DNA topoisomerase I (TOP1)
TW202426058A+DiS-Compound -145+Linker
[323]
mC-VA-Compound140
TW202426058A+MC-VA-Compound140+payload
Undisclosed
Mc-Val-Ala
[323]
nHC-C-VA-Compound140
10NH2-11F-Camptothecin
DNA topoisomerase I (TOP1)
TW202426058A+NHC-C--VA-Compound140+Linker
[323]
cN115160403A B1
CN115160403A+B1+payload
DNA topoisomerase I (TOP1)
Mc-Gly-Gly-Phe-Gly
[326]
cN115160403A B2
CN115160403A+B2+payload
Undisclosed
Mc-Gly-Gly-Phe-Gly
[326]
cN115160403A B3
CN115160403A+B3+payload
Undisclosed
Mc-Gly-Gly-Phe-Gly
[326]
cN115160403A B4
CN115160403A+B4+payload
Undisclosed
Mc-Gly-Gly-Phe-Gly
[326]
cN115160403A B5
CN115160403A+B5+payload
Undisclosed
Mc-Gly-Gly-Phe-Gly
[326]
cN115160403A B6
CN115160403A+B6+payload
Undisclosed
Mc-Gly-Gly-Phe-Gly
[326]
cN115160403A B7
CN115160403A+B7+payload
DNA topoisomerase I (TOP1)
Mc-Gly-Gly-Phe-Gly
[326]
cN115160403A B8
CN115160403A+B8+payload
Undisclosed
Mc-Gly-Gly-Phe-Gly
[326]
cN115160403A B9
CN115160403A+B9+payload
Undisclosed
CN115160403A+B9+Linker
[326]
cN115160403A B10
CN115160403A+B9+payload
Undisclosed
CN115160403A+B10+Linker
[326]
cN115160403A B11
CN115160403A+B9+payload
Undisclosed
CN115160403A+B11+Linker
[326]
cN115160403A B12
CN115160403A+B9+payload
Undisclosed
CN115160403A+B12+Linker
[326]
cN115160403A B13
(4-NH2)-Exatecan
DNA topoisomerase I (TOP1)
CN115160403A+B11+Linker
[326]
cN115160403A B14
CN115160403A+B1+payload
DNA topoisomerase I (TOP1)
CN115160403A+B14+Linker
[326]
cN115160403A B15
CN115160403A+B1+payload
DNA topoisomerase I (TOP1)
CN115160403A+B15+Linker
[326]
cN115160403A B16
CN115160403A+B7+payload
DNA topoisomerase I (TOP1)
CN115160403A+B11+Linker
[326]
cN115160403A B17
CN115160403A+B7+payload
DNA topoisomerase I (TOP1)
CN115160403A+B17+Linker
[326]
cN115160403A B18
CN115160403A+B7+payload
DNA topoisomerase I (TOP1)
CN115160403A+B18+Linker
[326]
cN115160403A B19
CN115160403A+B19+payload
Undisclosed
CN115160403A+B19+Linker
[326]
cN115160403A B20
CN115160403A+B20+payload
Undisclosed
CN115160403A+B20+Linker
[326]
cN115160403A B21
CN115160403A+B20+payload
Undisclosed
CN115160403A+B19+Linker
[326]
cN115160403A B22
CN115160403A+B20+payload
Undisclosed
CN115160403A+B22+Linker
[326]
cN115160403A B23
CN115160403A+B19+payload
Undisclosed
CN115160403A+B22+Linker
[326]
cN115160403A B24
CN115160403A+B19+payload
Undisclosed
CN115160403A+B24+Linker
[326]
cN115160403A B25
CN115160403A+B20+payload
Undisclosed
CN115160403A+B24+Linker
[326]
igG2a-Val-Cit-Pab-MMAE
Monomethyl auristatin E
Microtubule (MT)
WO2024102603A1+lgG2a-Val-Cit-Pab-MMAE+Linker
[332]
wO2024118785A3 Lot22
Undisclosed
Undisclosed
Undisclosed
[334]
wO2024118785A3 Lot23
Undisclosed
Undisclosed
Undisclosed
[334]
wO2024118785A3 Lot24
P9
Undisclosed
Undisclosed
[334]
wO2024118785A3 Lot34
Undisclosed
Undisclosed
Undisclosed
[334]
wO2024118785A3 Lot36
Undisclosed
Undisclosed
Undisclosed
[334]
wO2024118785A3 Lot38
Undisclosed
Undisclosed
Undisclosed
[334]
wO2024118785A3 Lot49
Undisclosed
Undisclosed
Undisclosed
[334]
wO2024118785A3 Lot50
P9
Undisclosed
Undisclosed
[334]
wO2024118785A3 Lot57
Undisclosed
Undisclosed
Undisclosed
[334]
wO2024118785A3 Lot61
P9
Undisclosed
Undisclosed
[334]
wO2024118785A3 Lot62
P9
Undisclosed
Undisclosed
[334]
wO2024118785A3 Lot70
Undisclosed
Undisclosed
Undisclosed
[334]
wO2024118785A3 Lot71
Undisclosed
Undisclosed
Undisclosed
[334]
wO2024118785A3 Lot77
Undisclosed
Undisclosed
Undisclosed
[334]
wO2024118785A3 Lot78
Undisclosed
Undisclosed
Undisclosed
[334]
wO2024118785A3 Lot79
Undisclosed
Undisclosed
Undisclosed
[334]
wO2024118785A3 Lot80
Undisclosed
Undisclosed
Undisclosed
[334]
wO2024118785A3 Lot91
Undisclosed
Undisclosed
Undisclosed
[334]
References
Ref 1 Ligand-cytotoxic drug conjugates and pharmaceutical uses thereof
Ref 2 B7h4 targeting antibody-drug conjugate and its use
Ref 3 Antibody drug conjugate
Ref 4 Antibody-drug conjugates
Ref 5 Antibody-drug conjugates
Ref 6 Targetted phototherapy with sensitizer-monoclonal antibody conjugate and light. Surg Oncol. 1993;2(1):31-42. doi: 10.1016/0960-7404(93)90042-w.
Ref 7 Self-reporting photodynamic nanobody conjugate for precise and sustainable large-volume tumor treatment
Ref 8 Detection of antidrug antibodies against antibody-drug conjugates by solid-phase extraction with acid dissociation in cynomolgus monkey serum
Ref 9 Harnessing acylhydrazone-oxime exchange reaction to achieve diverse synthesis of glycosite-specific antibody-drug conjugates
Ref 10 Methods for producing antibody-linker conjugates
Ref 11 Development of a severe combined immunodeficiency (SCID) mouse model consisting of highly disseminated human B-cell leukemia/lymphoma, cure of the tumors by systemic administration of immunotoxin, and development/application of a clonotype-specific polymerase chain reaction-based assay. Cancer Res. 1997 Feb 15;57(4):678-85.
Ref 12 AMHRII antibody-drug conjugates and uses thereof
Ref 13 Aminobenzazepine compounds, immunoconjugates, and uses thereof
Ref 14 Antibody drug conjugates with enzymatically cleavable groups
Ref 15 Anti-IL-13R&alpha;2 conjugates
Ref 16 A simple and highly sensitive LC-MS workflow for characterization and quantification of ADC cleavable payloads
Ref 17 Preparation and use of anti-FSHR antibody and antibody-drug conjugate thereof
Ref 18 A CD6-targeted antibody-drug conjugate as a potential therapy for T cell-mediated disorders
Ref 19 CD6-targeted antibody-drug conjugate as a new therapeutic agent for T cell lymphoma
Ref 20 Development of Apoptotic-Cell-Inspired Antibody-Drug Conjugate for Effective Immune Modulation
Ref 21 Rifamycin analogs and antibody-drug conjugates thereof
Ref 22 Hydrophilic linkers for antibody-drug conjugates
Ref 23 Site-Specific Antibody Conjugation Using Modified Bisected N-Glycans: Method Development and Potential toward Tunable Effector Function
Ref 24 Antibody-drug conjugates
Ref 25 Antibody-drug conjugates of N-oxacycloalkyl substituted camptothecin derivatives
Ref 26 Antibody-drug conjugates, their preparation methods and applications
Ref 27 Anti-tissue factor antibody conjugated with monomethyl auristatin E or deruxtecan in pancreatic cancer models
Ref 28 Cryptophycin antibody conjugates for the treatment of cancer
Ref 29 Antibody-drug conjugates
Ref 30 Antibody-drug conjugates containing an anti-mesothelin antibody and uses thereof
Ref 31 IGF-1R antibody-drug conjugate and its use for the treatment of cancer
Ref 32 Bifunctional cytotoxic agents containing the CTI pharmacophore
Ref 33 Ph-dependent Anti-sulfated glycosaminoglycan antibody and antibody-drug conjugate
Ref 34 A pharmaceutical composition and its applications
Ref 35 KK2845, a PBD dimer-containing antibody-drug conjugate targeting TIM-3-expressing AML
Ref 36 Application of ALK inhibitors together with EGFR-targeted antibody-drug conjugates in the preparation of medicines for treating lung cancer
Ref 37 Anti-GLP1R antibody-drug conjugates comprising GLP-1 peptidomimetics and uses thereof
Ref 38 Antibody-drug conjugate
Ref 39 Use of hydroxypropyl-&beta;-cyclodextrin in stabilizing antibody-drug conjugate formulations
Ref 40 A disruptive clickable antibody design for the generation of antibody-drug conjugates
Ref 41 Conditional activation of an anti-IgM antibody-drug conjugate for precise B cell lymphoma targeting
Ref 42 Nitroaryl-based linkers, antibody-drug conjugates comprising the linkers and uses thereof
Ref 43 Conjunctive therapy for treating tumor antigen expression cancer
Ref 44 Calicheamicin derivatives and antibody drug conjugates thereof
Ref 45 MSLN antibody-drug conjugate
Ref 46 Diazaborines Are a Versatile Platform to Develop ROS-Responsive Antibody Drug Conjugates*. Angew Chem Int Ed Engl. 2021 Dec 1;60(49):25914-25921. doi: 10.1002/anie.202109835. Epub 2021 Nov 5.
Ref 47 Isoindolinone-glutarimide antibody conjugates, and uses thereof
Ref 48 Antibodies against monomethyl auristatin E and uses thereof
Ref 49 New shielded antibody
Ref 50 Antibody-drug conjugates cleavable in a tumor microenvironment
Ref 51 An antibody-photosensitiser bioconjugate overcomes trastuzumab resistance in HER2-positive breast cancer
Ref 52 Anti-CD45 PBD-based antibody-drug conjugates are effective targeted conditioning agents for gene therapy and stem cell transplant
Ref 53 A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
Ref 54 Introduction to basic information on ADC drug 131I-ImmuRAIT-HCG (Immunomedics).
Ref 55 NewBio Therapeutics company product pipeline
Ref 56 RemeGen biopharmaceutical company clinical-stage drug candidates and selected IND-enabling stage candidates; 30 Jun 2022.
Ref 57 Evopoint biosciences product pipeline
Ref 58 Introduction to basic information on ADC drug bi-specific antibody drug conjugates(Zymeworks).
Ref 59 Introduction to basic information on ADC drug ZV03-ADC.
Ref 60 Y-Biologics biotechnology company product pipeline
Ref 61 Introduction to basic information on ADC drug BC5084 by Veri.larvol.
Ref 62 Westlake therapeutics product pipeline
Ref 63 ADC review: basic information about VIS705.
Ref 64 Introduction to basic information on ADC drug second ADC (Virtuoso Therapeutics).
Ref 65 Introduction to basic information on ADC drug lead ADC (Virtuoso Therapeutics).
Ref 66 Introduction to basic information on ADC drug additional ADCs (Virtuoso Therapeutics).
Ref 67 Introduction to basic information on ADC drug VLS-301.
Ref 68 Introduction to basic information on ADC drug VLS-201.
Ref 69 Introduction to basic information on ADC drug Vas-202.
Ref 70 Introduction to basic information on ADC drug Vas-201.
Ref 71 Vaccinex and catalent biologics to collaborate on ADC development; 2017
Ref 72 https://tubulis.com/
Ref 73 Tot biopharm annual announcement; 2021
Ref 74 Topmunnity therapeutics company product pipeline
Ref 75 ADC review: basic information about TGM-005.
Ref 76 ADC review: basic information about TGM-004.
Ref 77 ADC review: basic information about TGM-003.
Ref 78 ADC review: basic information about TGM-002.
Ref 79 TAE Life Sciences company product pipeline
Ref 80 Introduction to basic information on ADC drug SI-M-005A.
Ref 81 Introduction to basic information on ADC drug SI-M-002A.
Ref 82 Introduction to basic information on ADC drug SI-B-004A.
Ref 83 ADC review: basic information about BL-B029A1.
Ref 84 ADC review: basic information about BL-M002A2.
Ref 85 Introduction to basic information on antibody-drug conjugate 4(Synthon).
Ref 86 Introduction to basic information on antibody-drug conjugate 3(Synthon).
Ref 87 Syntab therapeutics biotechnology company product pipeline
Ref 88 Next generation drug conjugates for cancer treatment.
Ref 89 Synaffix is a biotechnology company product pipeline
Ref 90 Medilink biotechnology company product pipeline
Ref 91 Introduction to basic information on BsAb-ADC (Medilink Therapeutics).
Ref 92 Antibody drug conjugates SOT106
Ref 93 Sirenas biotechnology company announcement; 2016
Ref 94 Introduction to basic information on ADC drug SMD-3117.
Ref 95 Huiyu pharma semi-annual report; 2022
Ref 96 Introduction to basic information on ADC drug BL-M005.
Ref 97 Biokin pharma Prospectus; 2022
Ref 98 Enduring biotechnology company product pipeline
Ref 99 Enduring biotechnology company product pipeline
Ref 100 Introduction to basic information on ADC drug SY-1558
Ref 101 Introduction to basic information on ADC drug MRG006.
Ref 102 Micurx biopharmaceutical company product pipeline
Ref 103 MabGen biotechnology company product pipeline
Ref 104 Sanofi and Seagen announce collaboration to develop and commercialize multiple novel antibody-drug conjugates; 2022
Ref 105 Introduction to basic information on ADC drug SGN-25.
Ref 106 Introduction to basic information on ADC drug APEC-3.
Ref 107 Introduction to basic information on ADC drug APEC-2.
Ref 108 Introduction to basic information on ADC drug RAD-501.
Ref 109 PrimeLink bio therapeutics product pipeline
Ref 110 PrecisemAb biotechnology company product pipeline
Ref 111 Introduction to basic information on ADC drug DN-028.
Ref 112 Introduction to basic information on ADC drug DN-027.
Ref 113 Pheno therapeutics product pipeline
Ref 114 Introduction to basic information on ADC drug antibody-drug conjugate containing OXS-2175(Oxis Biotech/MultiCell ImmunoTherapeutics).
Ref 115 Introduction to basic information on ADC drug OX-004.
Ref 116 Oxford biotherapeutics and boehringer ingelheim agree on 2 year extension to their second multi-year collaboration in cancer immunology; 2023
Ref 117 Oxford Biotherapeutics product pipeline
Ref 118 Introduction to basic information on next generation antibody-drug conjugates(Oxford BioTherapeutics).
Ref 119 NewBio Therapeutics company product pipeline
Ref 120 NewBio Therapeutics company product pipeline
Ref 121 NewBio Therapeutics company product pipeline
Ref 122 NewBio Therapeutics company product pipeline
Ref 123 Introduction to basic information on ADC drug NW-12-005.
Ref 124 Nectin therapeutics biotechnology company product pipeline
Ref 125 Antibody drug conjugates SOT107
Ref 126 Introduction to basic information on ADC drug NBE-003.
Ref 127 Introduction to basic information on ADC drug NBE-001.
Ref 128 Introduction to basic information on ADC drug MBC-301
Ref 129 Introduction to basic information on ADC drug G-100 (Magenta Therapeutics).
Ref 130 Mablink bioscience company product pipeline
Ref 131 Legochem biosciences biopharmaceutical company product pipeline
Ref 132 ADC review: basic information about LCB14-15NM.
Ref 133 Legochem biosciences: Biopharmaceutical company with robust milestone potential; 2019
Ref 134 Introduction to basic information on ADC drug LP-A18.
Ref 135 Lanova medicines biotechnology company product pipeline
Ref 136 Introduction to basic information on ADC drug LIN-003.
Ref 137 Kangabio biotechnology company product pipeline
Ref 138 Introduction to basic information on ADC drug IOG-101.
Ref 139 Introduction to basic information on ADC drug DBAF-301.
Ref 140 Introduction to basic information on ADC drug IN30718.
Ref 141 Immunobiochem biotechnology company product pipeline
Ref 142 Iksuda therapeutics product pipeline
Ref 143 Introduction to basic information on ADC drug glaucoma therapy(Houston).
Ref 144 Heidelberg pharma product pipeline
Ref 145 DAC biotechnology company product pipeline
Ref 146 Kind Pharmaceuticals LLC company product pipeline.
Ref 147 Introduction to basic information on ADC drug Gbm12401.
Ref 148 Introduction to basic information on ADC drug GMA-305.
Ref 149 Gmax biopharm biopharmaceutical company product pipeline
Ref 150 Research programme: glycodesigned biotherapeutics (SeeloMab-GEX)-Glycotope; 28 Mar 2018.
Ref 151 Oligomerization improves endostatin as antiangi-ogenic and anticancer drug (P-1000)
Ref 152 Introduction to basic information on ADC drug GL-231
Ref 153 Introduction to basic information on ADC drug GF-2014.
Ref 154 Genequantum biopharmaceutical company product pipeline
Ref 155 Futuregen biopharmaceutical company product pipeline
Ref 156 EvolveImmune therapeutics product pipeline
Ref 157 ADC review: basic information about EP-400.
Ref 158 Epinogen biotechnology company product pipeline
Ref 159 Safety Assessment of Antibody Drug Conjugates.
Ref 160 Defence Therapeutics company product pipeline in Development.
Ref 161 Introduction to basic information on ADC drug CM-09(Curemeta).
Ref 162 Cstone pharma product pipeline
Ref 163 Introduction to basic information on ADC drug CBP-1609.
Ref 164 Introduction to basic information on ADC drug Antiviral Fc-conjugates(Cidara Therapeutics).
Ref 165 Introduction to basic information on ADC drug CRB-2107.
Ref 166 Introduction to basic information on ADC drug monoclonal Antibody-Drug Conjugates(Celltrion Chemical Research Institute/Immunogen/Celltrion).
Ref 167 Introduction to basic information on ADC drug CT-P26.
Ref 168 Introduction to basic information on ADC drug CAT-03-106.
Ref 169 Introduction to basic information on ADC drug BMT-125961.
Ref 170 Brickbio biotechnology company product pipeline
Ref 171 boostimmune biotechnology company product pipeline
Ref 172 Blueshield pharma product pipeline
Ref 173 Introduction to basic information on ADC drug BSC-4201.
Ref 174 Introduction to basic information on ADC drug BSC-4101
Ref 175 Introduction to basic information on ADC drug BSI-023.
Ref 176 Introduction to basic information on ADC drug BIOO-4.
Ref 177 Introduction to basic information on ADC drug BIOO-3.
Ref 178 Introduction to basic information on ADC drug BIOO-2.
Ref 179 Introduction to basic information on ADC drug BIOO-1.
Ref 180 Biocytogen biotechnology company product pipeline
Ref 181 Introduction to basic information on advanced antibody drug conjugates(Belrose Pharma).
Ref 182 Neoletix biotechnology company product pipeline
Ref 183 Introduction to basic information on ADC drug JY-023.
Ref 184 Axcynsis therapeutics product pipeline
Ref 185 Introduction to basic information on ADC drug AT-00
Ref 186 AVIPEP Therapeutics product pipeline
Ref 187 Introduction to basic information on ADC drug Antibody drug conjugate containing duocarmycin analogue
Ref 188 Research programme : antibody drug conjugate-Halozyme; 28 Feb 2021.
Ref 189 Introduction to basic information on ADC drug APB-CS
Ref 190 Introduction to basic information on advanced antibody drug conjugates(Belrose Pharma).
Ref 191 Introduction to basic information on monoclonal antibody-drug conjugate(Antengene).
Ref 192 Introduction to basic information on monoclonal anti-cancer therapeutic (Amgen).
Ref 193 Introduction to basic information on ADC drug AK 30 NGF; 27 Nov 2000.
Ref 194 AIMEDBIO biotechnology company product pipeline.
Ref 195 Adcentrx therapeutics product pipeline
Ref 196 ADC review: basic information about ABGN-108.
Ref 197 Exelixis and Ryvu Therapeutics Establish Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies; 2022
Ref 198 ADC review: basic information about BL-M005A2.
Ref 199 Xiling yuan pharmaceutical company product pipeline
Ref 200 Cybrexa therapeutics product pipeline
Ref 201 Post translational modification therapeutics product pipeline
Ref 202 Aphios biotechnology company product pipeline
Ref 203 An antibody-drug conjugate carrying a microtubule inhibitor and a DNA alkylator exerts both mechanisms of action on tumor cells. Cancer Res (2019) 79 (13_Supplement): 232.
Ref 204 Heidelberg pharma ATACs fighting cancer; 2020
Ref 205 Combination of antibody-targeted amanitin conjugates (ATAC) with immune checkpoint inhibitors shows synergistic therapeutic effect in vitro and in vivo. Cancer Res (2021) 81 (13_Supplement): 921.
Ref 206 Introduction to basic information on alpha-amanitin antibody-drug conjugates(Agensys).
Ref 207 Introduction to basic information on eribulin ADC (Jiangsu hengrui)
Ref 208 Adagene and ADC therapeutics announce SAFEbody license agreement; 2019
Ref 209 Introduction to basic information on ADC drug Spliceostatin-antibody-drug conjugate
Ref 210 Mersana biopharmaceutical company product pipeline
Ref 211 F-star biotechnology company product pipeline
Ref 212 Introduction to basic information on ADC drug EX108.
Ref 213 Introduction to basic information on ADC drug ADC2313
Ref 214 Introduction to basic information on ADC drug ADC2154
Ref 215 Introduction to basic information on ADC drug ADC2231
Ref 216 Introduction to basic information on ADC drug ADC2335
Ref 217 Introduction to basic information on ADC drug ADC2317
Ref 218 Bliss Biopharmaceutical company product pipeline
Ref 219 Manhattan biotech company product pipeline
Ref 220 Pinotbio biotechnology company product pipeline
Ref 221 Symray biopharmaceutical company product pipeline
Ref 222 Brickbio biotechnology company product pipeline
Ref 223 Introduction to basic information on ADC drug AMB-101
Ref 224 AmMax biotechnology company product pipeline
Ref 225 JINFA pharmaceutical company product pipeline
Ref 226 Immune checkpoint inhibition combined with targeted therapy using a novel virus-like drug conjugate induces complete responses in a murine model of local and distant tumors. Cancer Immunol Immunother. 2023 Jul;72(7):2405-2422. doi: 10.1007/s00262-023-03425-3. Epub 2023 Mar 30.
Ref 227 ADC review IMB-202
Ref 228 Introduction to basic information on ADC drug 3-NAntC
Ref 229 Boostimmune R&D pipeline.
Ref 230 Progression towards the clinic by 2025 with a strategy for rapid FIH data acquisition.
Ref 231 An overview of BR107.
Ref 232 Bioray R&D pipeline.
Ref 233 An overview of BRY811.
Ref 234 Denali Therapeutics 2021.
Ref 235 Inxmed R&D pipeline.
Ref 236 An overview of NW-001.
Ref 237 FutureGen R&D pipeline.
Ref 238 Arbelebio R&D pipeline.
Ref 239 Transcenta Holding Limited 2022 annual report.
Ref 240 Cstonepharma R&D pipeline.
Ref 241 Introduction to basic information on ADC drug monovalent azymatic antibody drug conjugate(Zymeworks).
Ref 242 Immunobiochem corporation partners with the centre for the commercialization of antibodies and biologics at the university of toronto to advance new antibody drug conjugates; 2016
Ref 243 Research programme: anticancer antibody drug conjugates - Advanced Proteome Therapeutics/University of Toronto; 28 Nov 2020.
Ref 244 Introduction to basic information on ADC drug multi-functional antibody drug conjugate combination therapeutics (Sutro Biopharma/Celgene).
Ref 245 Introduction to basic information on ADC drug MRG009.
Ref 246 Introduction to basic information on ADC drug MRG008.
Ref 247 Introduction to basic information on ADC drug MRG007.
Ref 248 Introduction to basic information on ADC drug MRG005.
Ref 249 ADC review: basic information about LCB14-2NM.
Ref 250 Introduction to basic information on ADC drug CYP-Ab.
Ref 251 Introduction to basic information on antibody drug conjugates(Sanofi).
Ref 252 Compugen's antibody drug conjugate program results presented; 19 Oct 2015.
Ref 253 University of Virginia spinoff neoantigenics announces collaboration with Pfizer, investment from CIT to develop antibody-based therapeutics for cancer; 2014
Ref 254 Meditope biosciences presentation; 2014
Ref 255 Introduction to basic information on ADC drug LIN-003.
Ref 256 Introduction to basic information on ADC drug LM-317.
Ref 257 Introduction to basic information on antibody drug conjugates(Intrexon).
Ref 258 Introduction to basic information on ADC drug CRC-02 targeting antibody-drug conjugate(Igenica).
Ref 259 Introduction to basic information on antibody-drug conjugates(Daiichi Sankyo).
Ref 260 Introduction to basic information on ADC drug Antibody drug conjugate (Asana BioSciences)
Ref 261 Introduction to basic information on ADC drug BIOO-7.
Ref 262 Introduction to basic information on ADC drug BIOO-6.
Ref 263 Introduction to basic information on ADC drug BIOO-5.
Ref 264 Bristol-myers squibb and ambrx announce collaboration for novel biologics programs in diabetes and heart failure
Ref 265 Introduction to basic information on antibodies conjugated to marine-derived cytotoxic payloads(Seattle Genetics).
Ref 266 Five prime therapeutics licenses antibodies to seattle genetics for use in novel antibody drug conjugate (ADC) programs; 2020
Ref 267 TOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor. Mol Cancer Ther. 2022 Jul 5;21(7):1090-1102.
Ref 268 Efficacy of DAN-222, a novel investigational polymeric nanoparticle with topoisomerase I inhibitor, as monotherapy in breast cancer models and when combined with PARP inhibitor. Journal of Clinical Oncology 2021 39:15_suppl, 1081-1081.
Ref 269 Introduction to basic information on ADC drug CHB-111.
Ref 270 ADC review: basic information about RG7986.
Ref 271 Introduction to basic information on ADC drug DS001
Ref 272 Novel immunotherapeutics against LGR5 to target multiple cancer types
Ref 273 A comparison of the activity, lysosomal stability, and efficacy of legumain-cleavable and cathepsin-cleavable ADC linkers
Ref 274 Optimization of a pendant-shaped PEGylated linker for antibody-drug conjugates
Ref 275 Generation and Characterization of SORT1-Targeted Antibody-Drug Conjugate for the Treatment of SORT1-Positive Breast Tumor
Ref 276 A high-affinity antibody-drug conjugates Actuximab-MMAE for potent and selective targeting of CEACAM5-Positive tumors
Ref 277 Digestion-Free Middle-Down Mass Spectrometry Method for Absolute Quantification of Conjugated Payload from Antibody-Drug Conjugates
Ref 278 Impact of drug-linker on method selection for analytical characterization and purification of antibody-drug conjugates
Ref 279 An auristatin-based antibody-drug conjugate targeting EphA2 in pancreatic cancer treatment
Ref 280 Antibody-Drug Conjugates of NLRP3 Agonists: How Overcoming Lysosomal Accumulation Necessitated Noncanonical Linker Attachments
Ref 281 Preparation of an Ultrahigh-DAR PDL1 monoclonal antibody-polymeric-SN38 conjugate for precise colon cancer therapy
Ref 282 Evaluating the Potential of Cyclodextrins in Reducing Aggregation of Antibody-Drug Conjugates with Different Payloads
Ref 283 A Novel Concept for Cleavable Linkers Applicable to Conjugation Chemistry - Design, Synthesis and Characterization
Ref 284 Targeted Delivery of TLR7 Agonists to the Tumor Microenvironment Enhances Tumor Immunity via Activation of Tumor-Resident Myeloid Cells
Ref 285 Tumor cell-directed STING agonist antibody-drug conjugates induce type III interferons and anti-tumor innate immune responses
Ref 286 CTLA-4 antibody-drug conjugate reveals autologous destruction of B-lymphocytes associated with regulatory T cell impairment
Ref 287 Novel antibody-antibiotic conjugate using KRM-1657 as payload eliminates intracellular MRSA in vitro and in vivo
Ref 288 Self-Immolative Carbamate Linkers for CD19-Budesonide Antibody-Drug Conjugates
Ref 289 Efficient intracellular drug delivery by co-administration of two antibodies against cell adhesion molecule 1
Ref 290 Photoactive immunoconjugates for targeted photodynamic therapy of cancer
Ref 291 Linker substitution influences succinimide ring hydrolysis equilibrium impacting the stability of attachment to antibody-drug conjugates
Ref 292 Shifting the Antibody-Drug Conjugate Paradigm: A Trastuzumab-Gold-Based Conjugate Demonstrates High Efficacy against Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Mouse Model
Ref 293 A thiol-selective and acid-stable protein modification strategy using an electron-deficient yne reagent
Ref 294 CTLA-4 antibody-drug conjugate reveals autologous destruction of B-lymphocytes associated with regulatory T cell impairment
Ref 295 Targeting GD2-Positive Tumor Cells by Pegylated scFv Fragment-Drug Conjugates Carrying Maytansinoids DM1 and DM4
Ref 296 Correction to: Method development of a novel PK assay for antibody-conjugated drug measurement of ADCs using peptide-linker drug analyte
Ref 297 proPBD-ADCs: optimization of therapeutic potential of ADCs based on capped PBD payload with attenuated potency
Ref 298 Preclinical development of ADCT-241, a novel exatecan-based antibody-drug conjugate targeting PSMA for the treatment of prostate cancer
Ref 299 Enhancing Topo1i ADC efficacy: development of homogeneous dual-payload ADCs combining Topo1i with microtubule inhibitors or PARP inhibitors
Ref 300 PA289, a prodrug linker-payload with a novel mechanism of action for the development of antibody drug conjugates
Ref 301 ThiOBI&reg; platform, a novel hydrophilic linker for irreversible cysteine-selective biomolecular conjugation, demonstrated potent and durable antitumor activities in various animal models
Ref 302 AMB304: A next generation ADC with topo I inhibitor, demonstrating robust preclinical efficacy against target overexpression tumors and high tolerability in non-human primate (NHP)
Ref 303 Identification of novel senolytic targets and development of conditionally active biologic-based-drug conjugates for targeted senescence-associated secretory phenotype elimination in vivo
Ref 304 A first-in-class KIF11 degrader antibody conjugate (DAC) as a potential therapy targeting a broad spectrum of cancers
Ref 305 Protein-drug conjugates comprising camptothecin analogs and methods of use thereof
Ref 306 Antibody-drug complexes
Ref 307 Pyrrolobenzodiazepine-anti-PSMA antibody conjugates
Ref 308 Antibody-drug conjugates targeting GCC
Ref 309 Anti-CD22 antibody-drug conjugates and methods of use
Ref 310 Conjugates targeting intracellular tumor-associated antigens for treatment of cancer
Ref 311 Antibody-drug conjugates
Ref 312 Immunomodulatory antibody drug conjugates binding to a human MICA polypeptide
Ref 313 Pro-antibody drug conjugates targeting EGFR-expressing tumor cells and their applications
Ref 314 Conjugates of antibodies and immune cell engagers
Ref 315 Pyrrolobenzodiazepine antibody conjugates
Ref 316 Prodrugs of topoisomerase I inhibitor for ADC conjugations and methods of use thereof
Ref 317 Neoantigen-eliciting antibody drug conjugates for the immunotherapy of cancer
Ref 318 Compositions and methods relating to molecular conjugates
Ref 319 Oligosaccharide linker, linker-payload comprising the same and glycan chain-remodeled antibody-drug conjugate, preparation methods and uses thereof
Ref 320 Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
Ref 321 Antibody-drug conjugates and production thereof
Ref 322 Antibody-drug conjugate compounds, and methods of use and treatment
Ref 323 Antibody-drug conjugates targeting phosphatidylinositol proteoglycan-3 and methods of use
Ref 324 Antibody-drug conjugates with masked PBD dimers
Ref 325 Cyclic dinucleotide derivatives and methods for preparing antibody-drug conjugates
Ref 326 Specific topoisomerase inhibitors and their use in antibody-drug conjugates and preparation methods
Ref 327 Methods and compositions for time-delayed bio-orthogonal release of cytotoxic agents
Ref 328 Antibody-drug conjugates
Ref 329 Branched linkers for antibody-drug conjugates and methods of use thereof
Ref 330 Antibody-drug conjugates based on microtubule inhibitors
Ref 331 Peptide tags, compositions and methods for site-specific protein conjugation
Ref 332 Bisecting-glycan bridged conjugation for producing glycoprotein conjugates
Ref 333 Bifunctional cytotoxins and uses thereof
Ref 334 TLR7 agonists and antibody-drug conjugates thereof
Ref 335 Intermediates of antibody-drug conjugates containing SN-38 and methods of preparation
Ref 336 Antibody-drug conjugate binding to human PTK7 and method for preparation and use thereof
Ref 337 Novel anti-TPBG antibody and antibody-drug conjugates based thereon, therapeutic methods and uses thereof
Ref 338 c-KIT antibody drug conjugates
Ref 339 Pharmaceuticals containing antibody-drug complexes containing hemiasterin derivatives
Ref 340 Site-specific conjugation of antibodies
Ref 341 An antibody-drug conjugate and its preparation method and application